{"meta":{"page":1,"per_page":50,"max_per_page":100,"total":1206,"total_is_capped":false,"direct_labels_cover":6,"predictions_cover":1206,"direct_label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline (scores rank; they never assert a category)","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"query_hash":"7976f2dfdd68","filters":{"topic":"PARP inhibition in cancer therapy"}},"results":[{"id":"W2897430921","doi":"10.1056/nejmoa1810858","title":"Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer","year":2018,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2839,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"AstraZeneca","keywords":"Olaparib; Medicine; Ovarian cancer; Oncology; Chemotherapy; Internal medicine; Disease; PARP inhibitor; Cancer; Maintenance therapy; Gynecology; Poly ADP ribose polymerase; Polymerase; Biology; Enzyme","retraction":null,"screen_n_in":null,"score":{"opus":0.01233339124823745,"gpt":0.2875400329087155,"spread":0.275206641660478,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004652026,0.0001806537,0.000572305,0.0002524431,0.00003719089,0.000005624685,0.0001624528,0.00006297189,0.0009824937],"category_scores_gemma":[0.0004589377,0.0001079981,0.00004074897,0.0003808564,0.0002225758,0.0001536182,0.00001410039,0.0004042731,0.000005660013],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000227414,"about_ca_system_score_gemma":0.0003821082,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002318346,"about_ca_topic_score_gemma":0.000321787,"domain_scores_codex":[0.9982705,0.00006102372,0.0005807381,0.0001757758,0.0006221372,0.0002897989],"domain_scores_gemma":[0.9982167,0.000147371,0.000420338,0.0002752921,0.0006017646,0.0003385121],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.03160864,0.0004082613,0.5533667,0.00006325376,0.0002490871,0.0005297994,0.003558992,0.0001390577,0.002065688,0.0003282158,0.05783935,0.349843],"study_design_scores_gemma":[0.4265202,0.008030143,0.4961724,0.003999267,0.0001247976,0.0001927044,0.0001178722,0.00002714741,0.0005608884,0.001302146,0.06276653,0.0001858869],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9784757,0.0008150126,0.001631299,0.01591935,0.001128985,0.0003045552,0.000004875823,0.00001456245,0.00170569],"genre_scores_gemma":[0.9894382,0.0003841402,0.002415441,0.003367862,0.003987787,0.000006098403,0.000005400157,0.00002861587,0.000366447],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3949116,"threshold_uncertainty_score":0.9999307,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2528228811","doi":"10.1056/nejmoa1611310","title":"Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer","year":2016,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2458,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University Health Centre; BC Cancer Agency; Princess Margaret Cancer Centre; University Health Network","funders":"Cilag; Genentech; PharmaMar; Medac; University College London; Clovis Oncology; Array BioPharma; USC Norris Comprehensive Cancer Center; Massachusetts Medical Society; Ohio State University; Teva Pharmaceutical Industries; Amgen; Pfizer; Myriad Genetics; AstraZeneca; Eli Lilly and Company; Mateon Therapeutics; GlaxoSmithKline","keywords":"Ovarian cancer; Platinum; Oncology; Maintenance therapy; Medicine; Internal medicine; Cancer; Chemotherapy; Chemistry; Biochemistry","retraction":null,"screen_n_in":null,"score":{"opus":0.03768055663310116,"gpt":0.3259895611761575,"spread":0.2883090045430563,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001010594,0.0001967931,0.0006415354,0.0003125807,0.00002753481,0.000004626818,0.0001492865,0.00008454944,0.001118653],"category_scores_gemma":[0.0004440318,0.00009922735,0.00008748116,0.0002796245,0.0001708692,0.0001201432,0.00001384536,0.0003930214,0.000007552162],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002993764,"about_ca_system_score_gemma":0.0004082589,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001673657,"about_ca_topic_score_gemma":0.0001052104,"domain_scores_codex":[0.9980479,0.0001278397,0.0007676253,0.0001888599,0.0005656001,0.00030217],"domain_scores_gemma":[0.9983075,0.0003110448,0.0004517918,0.0002655843,0.0003457256,0.000318416],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.008868541,0.0001156956,0.02324973,0.00001864077,0.0001480818,0.0005575253,0.001631789,0.000007104503,0.07047692,0.0003562597,0.05158211,0.8429876],"study_design_scores_gemma":[0.3918284,0.00659357,0.1122801,0.01200459,0.0001005879,0.003434519,0.0002609536,0.00002774334,0.02019523,0.005264618,0.4476508,0.00035889],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.80565,0.0063726,0.00333786,0.1770473,0.002928662,0.000414322,0.00001491971,0.00002825942,0.004206107],"genre_scores_gemma":[0.9747288,0.013911,0.0006747602,0.003058916,0.006587832,0.000006249556,0.000001824575,0.00002773491,0.001002889],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8426287,"threshold_uncertainty_score":0.9997945,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2975141952","doi":"10.1056/nejmoa1910962","title":"Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer","year":2019,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2262,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University Health Centre; McGill University","funders":"Eisai; Pacira BioSciences; Mylan; Clovis Oncology; Pacira Pharmaceuticals; Karyopharm Therapeutics; F. Hoffmann-La Roche; Roche; GlaxoSmithKline; Takeda Oncology; Amgen; Pfizer; Fujirebio US; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Ovarian cancer; Medicine; Oncology; Cancer; Gynecology; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.01026469645237137,"gpt":0.2782807913748217,"spread":0.2680160949224503,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000383447,0.0001661583,0.0006082073,0.0002781984,0.00001670637,0.000004747011,0.0001357379,0.00006271848,0.001668294],"category_scores_gemma":[0.0001826074,0.0001010399,0.00004476717,0.0003183011,0.00006098287,0.0001510453,0.00001133962,0.0004387088,0.000008813256],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001857474,"about_ca_system_score_gemma":0.0003523853,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001863432,"about_ca_topic_score_gemma":0.00009214768,"domain_scores_codex":[0.998358,0.00005648608,0.0005354158,0.0001575359,0.0006637251,0.0002288611],"domain_scores_gemma":[0.9986111,0.0001781272,0.0003745392,0.0002676527,0.0002827267,0.000285853],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01242977,0.0002132252,0.8585938,0.00005543583,0.0001419796,0.0001785674,0.001280801,0.0006061533,0.001474997,0.0001093831,0.008111889,0.116804],"study_design_scores_gemma":[0.4066121,0.005027787,0.5546208,0.002615581,0.00009962523,0.0000961655,0.000100933,0.00001899844,0.000268321,0.0005613969,0.02983254,0.0001457515],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9865412,0.001119252,0.000228133,0.009312531,0.0009354634,0.0003656272,0.000003281134,0.00001043467,0.001484041],"genre_scores_gemma":[0.9943871,0.000377085,0.001025259,0.002284606,0.001433182,0.000004628821,0.000008524545,0.00002697788,0.000452647],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3941823,"threshold_uncertainty_score":0.9992443,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2737389832","doi":"10.1016/s1470-2045(17)30469-2","title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1863,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"European Society for Medical Oncology","keywords":"Olaparib; Medicine; BRCA mutation; Ovarian cancer; Internal medicine; Oncology; Placebo; PARP inhibitor; Clinical endpoint; Population; Randomized controlled trial; Cancer; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.05211112076256093,"gpt":0.3733703096465478,"spread":0.3212591888839869,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001682879,0.0003670365,0.001584582,0.0001484887,0.0004386177,0.0000924792,0.0002797686,0.0002910678,0.0001850112],"category_scores_gemma":[0.0003290029,0.0002299431,0.000100233,0.0001505273,0.0005417186,0.0002401191,0.00004959268,0.0006896918,0.00001844471],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004338318,"about_ca_system_score_gemma":0.0006244626,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008258184,"about_ca_topic_score_gemma":0.0007803391,"domain_scores_codex":[0.9973008,0.0004661643,0.0006501529,0.0005628604,0.0003848895,0.0006351458],"domain_scores_gemma":[0.9971354,0.0006848363,0.0009266972,0.000809251,0.0002961268,0.0001477079],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9785604,0.0007137279,0.001897945,0.00002032379,0.0004332087,0.0001393949,0.001549875,0.00003959517,0.0006978901,0.0004580743,0.001167218,0.01432233],"study_design_scores_gemma":[0.9805862,0.005681535,0.006925271,0.0002154181,0.0001562721,0.0000727819,0.0001087261,0.0002634831,0.0007082772,0.0003432124,0.004665223,0.00027359],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9710769,0.0002094362,0.0001065273,0.01176316,0.000689771,0.008455561,0.00005653547,0.00006344953,0.007578632],"genre_scores_gemma":[0.9910946,0.0006242977,0.0003184927,0.003515606,0.001021563,0.002676675,0.00005808782,0.00005352461,0.0006371356],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02001769,"threshold_uncertainty_score":0.9376807,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1966928113","doi":"10.1126/science.1072221","title":"Mediation of Poly(ADP-Ribose) Polymerase-1-Dependent Cell Death by Apoptosis-Inducing Factor","year":2002,"lang":"en","type":"article","venue":"Science","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1812,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université Laval","funders":"","keywords":"Poly ADP ribose polymerase; Apoptosis-inducing factor; Programmed cell death; Apoptosis; Mitochondrion; Cell biology; Caspase; Biology; Molecular biology; Polymerase; Chemistry; Biochemistry; DNA","retraction":null,"screen_n_in":null,"score":{"opus":0.03233130338969271,"gpt":0.2929682653358566,"spread":0.2606369619461639,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002660044,0.000122802,0.0001871781,0.0001888781,0.0001339893,0.00002369327,0.0002140877,0.00005662993,0.001076296],"category_scores_gemma":[0.00007335786,0.000109797,0.00005069784,0.0005519825,0.0002445915,0.0002763103,0.00003233025,0.0001344807,0.00007850907],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002189711,"about_ca_system_score_gemma":0.000135133,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00006522503,"about_ca_topic_score_gemma":0.000001054742,"domain_scores_codex":[0.998084,0.00002411376,0.0002741991,0.0003623981,0.0009241739,0.0003310804],"domain_scores_gemma":[0.99911,0.00005012562,0.0001642438,0.000346847,0.0001208769,0.0002078555],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.00001178159,0.000113914,0.004751786,0.00001773229,0.000003924305,9.93506e-7,0.0007129794,0.000001989562,0.9878082,0.00002723352,0.0008890348,0.005660411],"study_design_scores_gemma":[0.0008534737,0.0001477369,0.003295284,0.00004358493,0.000009669031,0.000006436454,0.0001072936,0.0003685743,0.99413,0.00002700641,0.0008991032,0.000111909],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9894776,0.001890492,0.000806274,0.00125864,0.0005482513,0.0002287238,0.00005335047,0.00005928931,0.005677326],"genre_scores_gemma":[0.9973926,0.0001484004,0.00057525,0.0005616151,0.0001648798,0.00001202513,0.000004779742,0.00001240681,0.001128063],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007914927,"threshold_uncertainty_score":0.9998369,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2754327139","doi":"10.1016/s0140-6736(17)32440-6","title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1704,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network","funders":"Janssen Biotech; National Cancer Institute; Stand Up To Cancer; EMD Serono; Genentech; ImmunoGen; Ajinomoto; Clovis Oncology; Amgen; American Association for Cancer Research; National Ovarian Cancer Coalition; Regeneron Pharmaceuticals; University College London; Cancer Research UK; Array BioPharma; Memorial Sloan-Kettering Cancer Center; Ajinomoto Pharmaceuticals; Roche; AbbVie; Merck; Ovarian Cancer Research Fund; AstraZeneca; OncoMed Pharmaceutical; Ovarian Cancer Research Fund Alliance; U.S. Department of Defense","keywords":"Medicine; Placebo; Oncology; Internal medicine; Ovarian carcinoma; Double blind; Ovarian cancer; Surgery; Cancer; Alternative medicine; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.11880331611037,"gpt":0.3994762313502411,"spread":0.2806729152398711,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002459422,0.0004221345,0.001473663,0.0001094954,0.0005453124,0.0002214231,0.0005058448,0.0001438528,0.0003118527],"category_scores_gemma":[0.0004653191,0.000246761,0.0005002679,0.00008218107,0.0001793905,0.000112975,0.00004385354,0.0002354778,0.00006165505],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003791445,"about_ca_system_score_gemma":0.0003858304,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008054234,"about_ca_topic_score_gemma":0.00006544769,"domain_scores_codex":[0.9974239,0.0003485322,0.0006251543,0.0005498357,0.0003560131,0.000696534],"domain_scores_gemma":[0.996181,0.0008737039,0.0004286541,0.002085778,0.0001732654,0.0002575755],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9733529,0.0005789365,0.00008820686,0.00001552158,0.0004136008,0.00004168225,0.00165615,0.000004931262,0.001759393,0.0002380399,0.01271884,0.009131816],"study_design_scores_gemma":[0.8574194,0.006539934,0.0002492248,0.0001264243,0.0001776497,0.00002781449,0.00005336974,0.000174462,0.003311016,0.0003529055,0.1313151,0.0002527437],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.927258,0.0007179033,0.001990178,0.04627028,0.001677842,0.01957042,0.0003724886,0.0001013094,0.002041642],"genre_scores_gemma":[0.9676169,0.0002003741,0.0009431456,0.002784961,0.004956685,0.01929114,0.00003898334,0.00006739749,0.004100477],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1185963,"threshold_uncertainty_score":0.9999985,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3093265161","doi":"10.1016/s0140-6736(10)60892-6","title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial","year":2010,"lang":"en","type":"article","venue":"The Lancet","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1636,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Susan G. Komen; Cancer Research Society; AstraZeneca","keywords":"Olaparib; Medicine; Tolerability; Breast cancer; Cohort; PARP inhibitor; Internal medicine; BRCA mutation; Oncology; Adverse effect; Nausea; Cancer; Poly ADP ribose polymerase; Polymerase; Biology; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.01882420731186658,"gpt":0.3056834608736979,"spread":0.2868592535618313,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000238951,0.0002097939,0.0005967083,0.00009794931,0.00009049934,0.0000233691,0.000156302,0.00009481687,0.0003228171],"category_scores_gemma":[0.00006923412,0.000126074,0.00004335701,0.0003879963,0.0003736143,0.0001857716,0.00003331649,0.0004485787,0.000002266353],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006687013,"about_ca_system_score_gemma":0.0003306019,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003047847,"about_ca_topic_score_gemma":0.0006393711,"domain_scores_codex":[0.9985518,0.00009410274,0.0003675884,0.0002996463,0.000335592,0.0003512127],"domain_scores_gemma":[0.9989133,0.0001251196,0.0002190696,0.0004839017,0.0001371651,0.0001213994],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4512128,0.002401829,0.2341996,0.0002698021,0.0004055471,0.00003963166,0.006161754,0.00006286072,0.01148572,0.0004925493,0.007507123,0.2857608],"study_design_scores_gemma":[0.5666901,0.003842456,0.3371645,0.001126581,0.0002874552,0.0001116498,0.0004374164,0.0001889716,0.08032095,0.0004023341,0.008599053,0.0008285542],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9890314,0.0002679055,0.00003718056,0.007888073,0.0005131182,0.001477052,0.0005645856,0.00004984495,0.0001707786],"genre_scores_gemma":[0.9965024,0.00001650376,0.000665454,0.0009241822,0.001289884,0.0002680219,0.00006225894,0.0000361959,0.0002350726],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2849323,"threshold_uncertainty_score":0.5141148,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2086038769","doi":"10.1038/nrc2812","title":"PARP inhibition: PARP1 and beyond","year":2010,"lang":"en","type":"review","venue":"Nature reviews. Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1311,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta; Université Laval","funders":"National Cancer Institute; Canadian Institutes of Health Research; National Institutes of Health; National Institute of General Medical Sciences; Canada Research Chairs","keywords":"Limelight; PARP1; Poly ADP ribose polymerase; Polymerase; Biology; Computational biology; Enzyme; Chemistry; Biochemistry","retraction":null,"screen_n_in":null,"score":{"opus":0.04985341091087907,"gpt":0.4307639022885119,"spread":0.3809104913776328,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0006850185,0.0009371674,0.004403134,0.0002788836,0.0001355351,0.00005943943,0.0001840717,0.002509954,0.001993557],"category_scores_gemma":[0.0001832365,0.0006592385,0.000999061,0.0007513019,0.0002492948,0.0001307154,0.00008468573,0.005179817,0.0002541472],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004025177,"about_ca_system_score_gemma":0.0008313715,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000006564102,"about_ca_topic_score_gemma":0.000024052,"domain_scores_codex":[0.9964055,0.000244143,0.001269811,0.001035923,0.0005337202,0.0005109073],"domain_scores_gemma":[0.9972774,0.0001775356,0.000904698,0.001021307,0.0002066284,0.0004124241],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00001277498,0.00003706247,0.000004746238,0.03546377,0.0001226974,0.00003594005,0.00002238759,4.964042e-9,0.000005293897,0.0003444133,0.06825292,0.895698],"study_design_scores_gemma":[0.0006740798,0.00006114603,0.000003153641,0.06694196,0.001950222,0.0005954836,0.000002004114,1.707823e-7,0.00001426134,0.0001146509,0.9290657,0.0005771345],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00000138557,0.9860038,0.000008877196,0.0009501805,0.001921924,0.003396622,0.000289109,0.0001150887,0.007312971],"genre_scores_gemma":[0.000001091412,0.9851359,0.0008007568,0.005491523,0.00384395,0.002333298,0.0003885119,0.0001644965,0.001840543],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.8951209,"threshold_uncertainty_score":0.9995859,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2557666746","doi":"10.1016/s1470-2045(16)30559-9","title":"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1200,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre; University Health Network","funders":"Cancer Research UK; Clovis Oncology; Ovarian Cancer Research Fund; Stand Up To Cancer; Healthway; U.S. Department of Defense; National Ovarian Cancer Coalition; Ovarian Cancer Research Fund Alliance; American Association for Cancer Research","keywords":"Open label; Oncology; Medicine; Internal medicine; Ovarian carcinoma; Platinum; Ovarian cancer; Clinical trial; Cancer; Chemistry","retraction":null,"screen_n_in":null,"score":{"opus":0.1468834883678543,"gpt":0.4311228869311657,"spread":0.2842393985633114,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001150592,0.0002327434,0.0007727897,0.0001212686,0.0001047013,0.0000373238,0.0005796755,0.0002370173,0.001007897],"category_scores_gemma":[0.000339951,0.0001415992,0.00004659438,0.000195227,0.0003100952,0.0002390186,0.0001493241,0.0004222669,0.0001539364],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007400271,"about_ca_system_score_gemma":0.000418356,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004780208,"about_ca_topic_score_gemma":0.0005523255,"domain_scores_codex":[0.9974452,0.0007046135,0.0005866885,0.0004881607,0.0002766014,0.0004987682],"domain_scores_gemma":[0.9979091,0.0007639191,0.0003131701,0.0007196538,0.0001359455,0.0001582655],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6919988,0.01199728,0.007571159,0.00003489165,0.0006844923,0.001704713,0.006598941,0.00001541807,0.07713088,0.05217449,0.07463478,0.07545417],"study_design_scores_gemma":[0.7415406,0.005069163,0.004681878,0.0001850904,0.0001027017,0.0002110055,0.0003704537,0.0003263455,0.007549476,0.002479778,0.2371656,0.0003179617],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9389584,0.00004559791,0.0001609815,0.04551269,0.002803525,0.00170189,0.0001864131,0.00007823498,0.01055228],"genre_scores_gemma":[0.9863991,0.0002041723,0.001874424,0.006392455,0.003567487,0.000322642,0.0001022633,0.00003761849,0.001099802],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1625308,"threshold_uncertainty_score":0.9999053,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2117964602","doi":"10.1016/s1470-2045(11)70214-5","title":"Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study","year":2011,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1113,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia; Juravinski Cancer Centre; Vancouver General Hospital; Hôtel-Dieu de Montréal; Centre Hospitalier de l’Université de Montréal; Université de Montréal; BC Cancer Agency; Princess Margaret Cancer Centre; Jewish General Hospital","funders":"AstraZeneca","keywords":"Medicine; Olaparib; Internal medicine; Tolerability; Breast cancer; Ovarian cancer; Oncology; BRCA mutation; PARP inhibitor; Clinical endpoint; Triple-negative breast cancer; Adverse effect; Response Evaluation Criteria in Solid Tumors; Cancer; Serous fluid; Phases of clinical research; Clinical trial","retraction":null,"screen_n_in":null,"score":{"opus":0.1110609224459381,"gpt":0.3838345029660907,"spread":0.2727735805201525,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005489644,0.0004359827,0.001580716,0.0001667605,0.0001725603,0.0000358586,0.0006359565,0.0001607938,0.001414203],"category_scores_gemma":[0.00008484234,0.0002312769,0.00004221551,0.0006834159,0.0002242908,0.0001734388,0.0001573509,0.0006481685,0.0000227457],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008835015,"about_ca_system_score_gemma":0.0007893453,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.006409036,"about_ca_topic_score_gemma":0.01118922,"domain_scores_codex":[0.9965909,0.0009409626,0.0007150738,0.0006441341,0.00037275,0.0007362462],"domain_scores_gemma":[0.9978771,0.0003595689,0.0005279848,0.0007264408,0.0002818153,0.0002271161],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.7266828,0.03020309,0.2116423,0.00007036807,0.0008462986,0.0003749674,0.01554461,0.000001817923,0.0002243253,0.00002249072,0.001875361,0.01251157],"study_design_scores_gemma":[0.473753,0.0114576,0.5127542,0.0001715633,0.0003452598,0.00003103232,0.0006887412,0.0001456352,0.0002365384,0.00002603242,0.0001521067,0.0002383171],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9882612,0.00004453457,0.00003544999,0.001467127,0.000726463,0.008553026,0.000432243,0.00007256788,0.0004073596],"genre_scores_gemma":[0.9952415,0.00008360401,0.0006702085,0.001332646,0.000299715,0.001924507,0.00008638415,0.00006379875,0.0002976539],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3011119,"threshold_uncertainty_score":0.9994987,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2074952360","doi":"10.1038/bjc.2012.451","title":"Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer","year":2012,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":852,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia","funders":"University of California, San Francisco; University of Texas MD Anderson Cancer Center; U.S. Public Health Service; National Cancer Institute; U.S. Department of Health and Human Services; Science Foundation Ireland; Conquer Cancer Foundation; National Institutes of Health; Stand Up To Cancer; Entertainment Industry Foundation","keywords":"Loss of heterozygosity; Homologous recombination; Ovarian cancer; Biology; Homologous chromosome; Cancer research; Breast cancer; DNA repair; BRCA2 Protein; Genome instability; Cancer; Genetics; Oncology; Allele; DNA; Gene; Medicine; DNA damage; Mutation; Germline mutation","retraction":null,"screen_n_in":null,"score":{"opus":0.01701151675669156,"gpt":0.2972541560484307,"spread":0.2802426392917391,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006840534,0.0001229841,0.0005590813,0.000199521,0.00002771938,0.000006652245,0.0001166942,0.0001263763,0.0006245752],"category_scores_gemma":[0.00005731716,0.0001380949,0.0002431727,0.0001497445,0.00007986455,0.0002371394,0.00002412931,0.0003479181,0.000001077259],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005657867,"about_ca_system_score_gemma":0.000339101,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003137201,"about_ca_topic_score_gemma":0.001109069,"domain_scores_codex":[0.9981972,0.0001460278,0.0008485314,0.0001337757,0.0003959156,0.0002785652],"domain_scores_gemma":[0.9984515,0.00005548038,0.0008232234,0.0001457604,0.0003784024,0.0001455784],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0008154996,0.0004570074,0.9438352,0.0003037892,0.0002302982,0.0001560112,0.0004941977,0.0001424326,0.02561756,0.00001706701,0.0005279734,0.02740298],"study_design_scores_gemma":[0.005503068,0.0003487917,0.9546437,0.002275036,0.0001318724,0.001343137,0.00003748447,0.00001465713,0.03444775,0.0001078142,0.001030882,0.0001158056],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.983996,0.013879,0.0001743968,0.000191048,0.001159454,0.000246565,0.0002194973,0.00001216829,0.000121854],"genre_scores_gemma":[0.9894378,0.009292345,0.0002479187,0.0002050944,0.0006849452,0.00002639822,0.000004653263,0.00002703056,0.00007383103],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02728718,"threshold_uncertainty_score":0.6838661,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2951058429","doi":"10.1093/annonc/mdz192","title":"A decade of clinical development of PARP inhibitors in perspective","year":2019,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":730,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Fundación Fero; Institute of Cancer Research; Prostate Cancer Foundation; Cancer Research UK; National Institute on Handicapped Research; Department of Health and Aged Care, Australian Government; Instituto de Salud Carlos III; National Institute for Health and Care Research","keywords":"Medicine; Perspective (graphical); Intensive care medicine; Medical physics; Artificial intelligence","retraction":null,"screen_n_in":null,"score":{"opus":0.5086532471183037,"gpt":0.6122749549852945,"spread":0.1036217078669908,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001761503,0.0002539472,0.004792005,0.0004991971,0.000007580404,6.646343e-7,0.000193537,0.0008054019,0.0001369686],"category_scores_gemma":[0.000559534,0.0002108655,0.0007149464,0.0004145347,0.0003214685,0.00002687852,0.00007814182,0.0005912249,0.00002595946],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002272482,"about_ca_system_score_gemma":0.006034455,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003699556,"about_ca_topic_score_gemma":0.00002794896,"domain_scores_codex":[0.9955678,0.000450219,0.00305332,0.0003878525,0.00029718,0.0002436029],"domain_scores_gemma":[0.9957876,0.0009679334,0.002189162,0.0003773144,0.0005822388,0.0000957911],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0003151231,0.0009869501,0.0003926357,0.009357343,0.0005856875,0.00001712173,0.0008920785,3.803282e-7,0.000008866622,0.0003641371,0.002528305,0.9845514],"study_design_scores_gemma":[0.001796232,0.002001109,0.0004006667,0.0163639,0.0002286696,0.00002406731,0.0002352826,3.218567e-7,0.0004998773,0.0001159456,0.9781865,0.0001473472],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00186881,0.9858162,0.000008455545,0.0003538299,0.0004597292,0.001019153,0.00003324054,0.000007097272,0.01043342],"genre_scores_gemma":[0.001238832,0.9966847,0.001423773,0.0002103754,0.0001884124,0.00007351047,0.00002491384,0.00003194073,0.0001235244],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.984404,"threshold_uncertainty_score":0.9996004,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2006806309","doi":"10.1073/pnas.0606528103","title":"Apoptosis-inducing factor mediates poly(ADP-ribose) (PAR) polymer-induced cell death","year":2006,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":717,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec","funders":"National Institutes of Health; University of Ottawa; National Institute of Neurological Disorders and Stroke; American Heart Association","keywords":"Apoptosis-inducing factor; Poly ADP ribose polymerase; Programmed cell death; Apoptosis; Cytoplasm; Cell biology; Mitochondrion; Biology; Chemistry; Polymerase; Biochemistry; Caspase; Enzyme","retraction":null,"screen_n_in":null,"score":{"opus":0.05769557500955475,"gpt":0.3235504315589136,"spread":0.2658548565493588,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006800445,0.0001718923,0.0002887011,0.0002957271,0.0002432398,0.00002681213,0.0005294259,0.0001480122,0.0000757853],"category_scores_gemma":[0.0001669292,0.0001182934,0.0001450268,0.0008660643,0.0004924709,0.0004069282,0.00007814501,0.0002674921,0.00000500059],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001122618,"about_ca_system_score_gemma":0.0001224685,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00006467342,"about_ca_topic_score_gemma":7.564608e-8,"domain_scores_codex":[0.9970948,0.000008017125,0.0005187765,0.000353769,0.001741108,0.0002835449],"domain_scores_gemma":[0.9988146,0.0001495841,0.000612484,0.00001633108,0.0003320032,0.00007492617],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0000287647,0.00008742807,0.02294037,0.00006558343,0.00001421079,7.361028e-9,0.0001279,0.000003148123,0.9711378,0.004476668,0.0009220886,0.000196065],"study_design_scores_gemma":[0.0005699725,0.00008651021,0.08344974,0.0001574996,0.00002259072,0.000008540285,0.00009878747,0.0000899718,0.9088973,0.006389488,0.0001178297,0.0001117303],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9762504,0.0004608064,0.00000122433,0.006849837,0.00006853843,0.000254294,0.00003146659,0.0000350942,0.01604834],"genre_scores_gemma":[0.9972505,0.00002728915,0.001065625,0.000666753,0.0005783496,0.00001935706,6.004805e-7,0.00001169369,0.000379849],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06224044,"threshold_uncertainty_score":0.4823866,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2059397580","doi":"10.1073/pnas.0606526103","title":"Poly(ADP-ribose) (PAR) polymer is a death signal","year":2006,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":636,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec","funders":"National Institutes of Health; National Institute of Neurological Disorders and Stroke; American Heart Association","keywords":"Poly ADP ribose polymerase; Programmed cell death; Apoptosis; Excitotoxicity; Chemistry; Cell biology; Biology; Molecular biology; Biochemistry; Polymerase; Enzyme","retraction":null,"screen_n_in":null,"score":{"opus":0.05115591992945612,"gpt":0.3345953264226731,"spread":0.283439406493217,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006490957,0.0001098517,0.0001923606,0.0001990246,0.0001724911,0.00001654884,0.0003867602,0.00009040526,0.0002049262],"category_scores_gemma":[0.00005642472,0.00007344614,0.0001217448,0.0007432451,0.0008010619,0.0002771262,0.00005474366,0.0001668746,0.000005469273],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006459265,"about_ca_system_score_gemma":0.00008625415,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003376095,"about_ca_topic_score_gemma":2.908889e-8,"domain_scores_codex":[0.997658,0.000003970383,0.0003676582,0.0002484063,0.001531472,0.0001904735],"domain_scores_gemma":[0.9992142,0.00006446181,0.0003715314,0.000009148327,0.0002953958,0.00004521546],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0000809851,0.0001282303,0.04312608,0.00006260783,0.00002922559,1.870102e-8,0.0001412572,0.000003878186,0.8835341,0.05403491,0.01838912,0.0004696291],"study_design_scores_gemma":[0.0004940702,0.00007141157,0.08534056,0.0001399159,0.00002040048,0.0000294157,0.00004241571,0.0001572368,0.8780228,0.03421424,0.001391907,0.00007560568],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9088415,0.001720209,0.000005369196,0.03030474,0.00003525442,0.0002691956,0.00004490458,0.00003179586,0.05874706],"genre_scores_gemma":[0.9946349,0.00001842247,0.001104843,0.002440022,0.0004328412,0.00001334683,2.391561e-7,0.0000063381,0.00134908],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0857934,"threshold_uncertainty_score":0.2995047,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2070758111","doi":"10.1074/jbc.m706734200","title":"PARP1-dependent Kinetics of Recruitment of MRE11 and NBS1 Proteins to Multiple DNA Damage Sites","year":2007,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":599,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université Laval; Hôtel-Dieu de Québec; Centre hospitalier de l'Université Laval; University of Alberta; Centre hospitalier universitaire de Québec","funders":"","keywords":"DNA damage; DNA; Kinetics; PARP1; Cell biology; Biology; Chemistry; Biophysics; Genetics; Poly ADP ribose polymerase; Physics; Polymerase","retraction":null,"screen_n_in":null,"score":{"opus":0.1017277491476446,"gpt":0.3504430346639978,"spread":0.2487152855163532,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004644216,0.0001117683,0.0003966111,0.00003806236,0.00001197685,0.00000328473,0.00009459586,0.0001456323,0.0001799801],"category_scores_gemma":[0.0003649948,0.00007505972,0.0001010499,0.00009418269,0.0001316866,0.00001756353,0.00004306558,0.000202664,7.640446e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007461958,"about_ca_system_score_gemma":0.00002909269,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000002308109,"about_ca_topic_score_gemma":8.129861e-7,"domain_scores_codex":[0.9987939,0.00002028543,0.000650501,0.0001218155,0.0002598874,0.0001535973],"domain_scores_gemma":[0.9988278,0.0001550071,0.0004392972,0.0001419672,0.0002332165,0.0002027149],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.001037062,0.0003575449,0.02016744,0.0001236686,0.00005199752,0.00004553567,0.00007318903,0.000003988469,0.9768154,0.000003643134,0.000111724,0.001208776],"study_design_scores_gemma":[0.001747818,0.001256653,0.02451854,0.0002154468,0.00002280959,0.0001191382,0.0001963659,0.000002492532,0.9701375,0.0000731691,0.001638704,0.00007134587],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9974273,0.0004785096,0.0006932432,0.0004132517,0.00003293922,0.0002682768,0.00002341621,0.000005983671,0.0006570169],"genre_scores_gemma":[0.9939635,0.0001701311,0.005406848,0.0001597682,0.0001948505,0.000005495718,0.000004382825,0.000006466876,0.00008853888],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006677915,"threshold_uncertainty_score":0.3060847,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2033816200","doi":"10.1016/s1470-2045(14)71135-0","title":"Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial","year":2014,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":544,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Juravinski Cancer Centre; Université Laval; Princess Margaret Cancer Centre","funders":"AstraZeneca","keywords":"Olaparib; Medicine; Carboplatin; Tolerability; Internal medicine; Regimen; Ovarian cancer; Chemotherapy; Oncology; Paclitaxel; Response Evaluation Criteria in Solid Tumors; Clinical endpoint; Phases of clinical research; Urology; Cancer; Randomized controlled trial; Cisplatin; Adverse effect","retraction":null,"screen_n_in":null,"score":{"opus":0.05582660886094198,"gpt":0.3904644590514653,"spread":0.3346378501905233,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001281428,0.0002325234,0.001104364,0.00005660988,0.0001607165,0.00001615391,0.0001585788,0.0001528323,0.0002255932],"category_scores_gemma":[0.0001444351,0.0001417746,0.0001402039,0.000159517,0.0002564161,0.00003593995,0.00001072852,0.0003257056,0.00001148917],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003122663,"about_ca_system_score_gemma":0.0004016482,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003397959,"about_ca_topic_score_gemma":0.0000995833,"domain_scores_codex":[0.9982433,0.0003865693,0.0003851531,0.0003359944,0.000205071,0.0004438811],"domain_scores_gemma":[0.9977868,0.001113923,0.0003330601,0.0004545813,0.0001961198,0.0001155066],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9269211,0.0005837316,0.00002367061,0.00004037392,0.000359983,0.000006240074,0.001097791,0.00001461533,0.003906357,0.002195641,0.0192545,0.04559604],"study_design_scores_gemma":[0.7619015,0.01912303,0.00007515105,0.00009453724,0.0001849673,0.00004039328,0.00006304402,0.001549748,0.007345175,0.000861339,0.2085955,0.0001656442],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8005265,0.0002836796,0.0281658,0.1340322,0.003014333,0.01416003,0.000240022,0.0003874321,0.01918997],"genre_scores_gemma":[0.9655396,0.0003215695,0.003448804,0.01981188,0.006624247,0.003494547,0.0001260518,0.00007640399,0.0005569159],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.189341,"threshold_uncertainty_score":0.5781399,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2935541805","doi":"10.1016/s1470-2045(19)30029-4","title":"Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":537,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Ovarian cancer; BRCA mutation; Oncology; Progressive disease; Chemotherapy; Progression-free survival; Population; Phases of clinical research; Carboplatin; Combination therapy; Surgery; Gastroenterology; Cancer; Cisplatin","retraction":null,"screen_n_in":null,"score":{"opus":0.2455515079193662,"gpt":0.4816545343169153,"spread":0.2361030263975491,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004694136,0.0002520478,0.001257124,0.00007377286,0.00007872333,0.00002044171,0.0003348143,0.0001907979,0.001321848],"category_scores_gemma":[0.00003485547,0.0001656186,0.0001200971,0.0001873798,0.0001532434,0.00007734291,0.00003460658,0.0001366985,0.00003799704],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006964681,"about_ca_system_score_gemma":0.0004957653,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004103262,"about_ca_topic_score_gemma":0.0002291894,"domain_scores_codex":[0.9981915,0.0002230188,0.0005562513,0.0003878538,0.0001722263,0.0004691967],"domain_scores_gemma":[0.9980692,0.0005486693,0.0004282607,0.0006918242,0.0001598669,0.0001021786],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7075873,0.02326378,0.0003626719,0.000117849,0.001269471,0.00001944347,0.002978139,0.0001194439,0.1236561,0.001597572,0.007833914,0.1311943],"study_design_scores_gemma":[0.5433815,0.03649398,0.00004203046,0.00006787481,0.0002166787,0.00001068652,0.00007202022,0.001340501,0.02303319,0.0005610614,0.3946285,0.0001520198],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9556818,0.001592967,0.0005653496,0.02727901,0.001913648,0.008377397,0.0003358841,0.0000790354,0.004174937],"genre_scores_gemma":[0.9699512,0.002940644,0.005932465,0.007960144,0.003465728,0.002719293,0.0001604646,0.0001032983,0.006766839],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3867946,"threshold_uncertainty_score":0.9995911,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2799710201","doi":"10.1186/s40169-018-0185-6","title":"Analyses of repeated failures in cancer therapy for solid tumors: poor tumor‐selective drug delivery, low therapeutic efficacy and unsustainable costs","year":2018,"lang":"en","type":"article","venue":"Clinical and Translational Medicine","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":486,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Institute of Aging","funders":"National Eye Institute; National Institutes of Health; Ministry of Education, Culture, Sports, Science and Technology; National Cancer Institute; University of Pennsylvania","keywords":"Medicine; Cancer; Drug; Drug delivery; Cancer therapy; Oncology; Intensive care medicine; Pharmacology; Internal medicine; Nanotechnology","retraction":null,"screen_n_in":null,"score":{"opus":0.09298064257482087,"gpt":0.4585024538825066,"spread":0.3655218113076857,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006856427,0.0001846136,0.0006876187,0.0001784903,0.00008031937,0.000005505756,0.00007254165,0.00008207396,0.0001391503],"category_scores_gemma":[0.0002147591,0.0001306433,0.00007674927,0.0003379545,0.001162919,0.00007084618,0.000008514715,0.000199685,5.854968e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002918886,"about_ca_system_score_gemma":0.0002700932,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005452676,"about_ca_topic_score_gemma":0.0001618436,"domain_scores_codex":[0.9981711,0.0001159606,0.0008153885,0.0003998081,0.0002547697,0.0002430094],"domain_scores_gemma":[0.9977586,0.001208077,0.0001840467,0.0001629255,0.0005302484,0.000156078],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.06003291,0.003179424,0.6037823,0.001028863,0.002457601,0.00007301687,0.005713608,0.00007739078,0.08653134,0.002866404,0.005901499,0.2283557],"study_design_scores_gemma":[0.05644977,0.006131914,0.8806061,0.002322461,0.0003857368,0.00003722227,0.0005166595,0.002869726,0.03167502,0.01455642,0.004077214,0.0003717659],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9721605,0.008991299,0.0003830713,0.01702773,0.0001114141,0.001045357,0.0000337355,0.00002618618,0.0002206723],"genre_scores_gemma":[0.9947361,0.001735145,0.0003648219,0.002335361,0.0005998434,0.00008627507,0.00003505901,0.00002098195,0.00008637501],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2768238,"threshold_uncertainty_score":0.5327481,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4295078726","doi":"10.1200/jco.22.01549","title":"Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":475,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; NRG Oncology; Sanofi; AstraZeneca","keywords":"Olaparib; Medicine; PARP inhibitor; Internal medicine; Ovarian cancer; Hazard ratio; Clinical endpoint; Oncology; Placebo; Cancer; Veliparib; BRCA mutation; Clinical trial; Surgery; Poly ADP ribose polymerase; Confidence interval; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.0555831528157147,"gpt":0.3980408485949811,"spread":0.3424576957792664,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002179637,0.0001772311,0.001160005,0.00009441567,0.0001478089,0.00001217312,0.0001758831,0.0001364124,0.000448143],"category_scores_gemma":[0.0009345552,0.000103304,0.0001749953,0.0002504745,0.0002944048,0.0001339617,0.00007866536,0.001233417,0.000001815685],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007488106,"about_ca_system_score_gemma":0.001994423,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001006044,"about_ca_topic_score_gemma":0.0009058964,"domain_scores_codex":[0.9965121,0.0007310529,0.001436605,0.0002891139,0.0007279065,0.0003032893],"domain_scores_gemma":[0.9952398,0.002318377,0.001628557,0.0002185164,0.0003681385,0.0002266054],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7321832,0.001613375,0.2398348,0.00001538597,0.000467736,0.0007390929,0.0007976691,0.00113173,0.0000121514,0.000289686,0.003683691,0.01923142],"study_design_scores_gemma":[0.5410072,0.03555233,0.3965478,0.0001344268,0.0001942548,0.0001262522,0.0003348113,0.00005206616,0.000004249408,0.0005021031,0.02539334,0.0001512317],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9829684,0.0001850977,0.0001138045,0.01338323,0.002006334,0.0008550347,0.00002133972,0.000008842786,0.0004579198],"genre_scores_gemma":[0.9923978,0.0002285536,0.001116289,0.005045392,0.0006198644,0.0001348221,0.000008043829,0.00002999538,0.0004191927],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.191176,"threshold_uncertainty_score":0.5358651,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2049028195","doi":"10.1126/scisignal.2000902","title":"Poly(ADP-Ribose) (PAR) Binding to Apoptosis-Inducing Factor Is Critical for PAR Polymerase-1–Dependent Cell Death (Parthanatos)","year":2011,"lang":"en","type":"article","venue":"Science Signaling","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":464,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Université Laval","funders":"National Institute of Neurological Disorders and Stroke; National Institute on Drug Abuse; Canadian Institutes of Health Research","keywords":"Poly ADP ribose polymerase; Apoptosis; Programmed cell death; Polymerase; Cell biology; Biology; Molecular biology; Ribose; Cancer research; Chemistry; Biochemistry; Enzyme","retraction":null,"screen_n_in":null,"score":{"opus":0.09824333107992472,"gpt":0.3517895159427005,"spread":0.2535461848627757,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00103607,0.0003354866,0.0004375185,0.0006008918,0.0008325215,0.0001384051,0.0004811878,0.0001301454,0.001128239],"category_scores_gemma":[0.0003245543,0.0003167085,0.0001897002,0.0009022976,0.0003713758,0.0005065658,0.0001050228,0.0002912126,0.000158829],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003527793,"about_ca_system_score_gemma":0.0006544234,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001326604,"about_ca_topic_score_gemma":0.000002353849,"domain_scores_codex":[0.9960867,0.00004397944,0.0005655443,0.001033391,0.001056487,0.001213935],"domain_scores_gemma":[0.9978768,0.000221404,0.0001362234,0.0005480725,0.0003471389,0.0008703652],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0001539807,0.0001387666,0.004212623,0.00006825768,0.00001885156,0.000009378179,0.003321041,0.000003063686,0.9899303,0.0004601653,0.0002267355,0.001456852],"study_design_scores_gemma":[0.001029339,0.0004750732,0.0005482582,0.0003133877,0.00005923421,0.00002062441,0.001040409,0.0002133132,0.9953231,0.0003189551,0.0002676708,0.0003905849],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9708543,0.0003238882,0.02276488,0.001348017,0.001026286,0.000814473,0.000122533,0.0001602801,0.002585392],"genre_scores_gemma":[0.9763138,0.000007841078,0.02001665,0.002744966,0.0005488462,0.0001250076,0.000005133327,0.00005275742,0.0001850568],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005459487,"threshold_uncertainty_score":0.9999285,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2085215116","doi":"10.1038/nbt.2121","title":"Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors","year":2012,"lang":"en","type":"article","venue":"Nature Biotechnology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":460,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; Structural Genomics Consortium","funders":"Canadian Institutes of Health Research; Wellcome Trust","keywords":"Olaparib; Poly ADP ribose polymerase; Polymerase; Small molecule; PARP inhibitor; Computational biology; Biology; Chemical biology; Chemistry; Biochemistry; Enzyme; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.008652512575361737,"gpt":0.2946905990793961,"spread":0.2860380865040343,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001327785,0.0001410352,0.0004178129,0.0004580704,0.00003030249,0.000003731218,0.00005338517,0.0010847,0.00001862458],"category_scores_gemma":[0.0001721587,0.0001161809,0.00006498091,0.0007277494,0.0003873704,0.00005627023,0.00006086767,0.0007246219,6.360027e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005040481,"about_ca_system_score_gemma":0.00002271446,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000008985678,"about_ca_topic_score_gemma":0.000001512049,"domain_scores_codex":[0.9991109,0.00001688152,0.0002340923,0.0002478974,0.0001456503,0.0002445916],"domain_scores_gemma":[0.9994188,0.00007374957,0.0001089417,0.0002480537,0.00005476572,0.0000956976],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0001245443,0.00002637524,0.1701696,0.00004872905,0.0004337889,0.000004471676,0.00007731209,3.716235e-7,0.8210552,0.003728139,0.0001854099,0.004146058],"study_design_scores_gemma":[0.0009354668,0.00007759275,0.06568885,0.00003225677,0.0005547783,0.00005840179,0.0001431418,0.0001452803,0.9303867,0.0002358733,0.001606722,0.0001349473],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9862391,0.01069028,0.00005779223,0.002475241,0.0001518236,0.0001757948,0.00002770111,0.00009095827,0.00009125556],"genre_scores_gemma":[0.9955381,0.0002492496,0.003488838,0.0005540467,0.0001083169,0.000008529313,0.00003133243,0.00001229149,0.000009293964],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1093315,"threshold_uncertainty_score":0.8366199,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4304084160","doi":"10.1016/j.annonc.2022.09.159","title":"Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":447,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto","funders":"Merck Sharp and Dohme; University of Illinois at Urbana-Champaign; National Institutes of Health; Karolinska Institutet; Clovis Oncology; National Institute for Health and Care Research; Seagen; Cilag; Puma Biotechnology; NRG Oncology; Les Laboratories Pierre Fabre; Institut Bergonié; Amgen; Rush University; University of Pennsylvania; Genentech; Institut Gustave-Roussy; Merck KGaA; Daiichi Sankyo Europe; National Cancer Institute; Servier; Gilead Sciences; School of Medicine, Indiana University; European Commission; Sanofi; Genomic Health; Ochsner Health; MSD; GlaxoSmithKline; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Olaparib; Internal medicine; Oncology; Placebo; Hazard ratio; Breast cancer; Confidence interval; Cancer; Pathology; Biology; Polymerase","retraction":null,"screen_n_in":null,"score":{"opus":0.03810809554894744,"gpt":0.3551060294228056,"spread":0.3169979338738582,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001322768,0.0001457178,0.0007256502,0.0002635102,0.0000337631,0.000003039407,0.0001448846,0.00009032188,0.0002654778],"category_scores_gemma":[0.00003559704,0.0001106884,0.00005070327,0.0004214112,0.0001564071,0.00007534803,0.00005925496,0.0004098042,3.947908e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001394147,"about_ca_system_score_gemma":0.0004614925,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.008189053,"about_ca_topic_score_gemma":0.002275627,"domain_scores_codex":[0.9976158,0.0007556461,0.000676829,0.0002785733,0.0003914986,0.0002816682],"domain_scores_gemma":[0.9989129,0.0002369156,0.000431712,0.0002519558,0.0001128772,0.00005360201],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.330544,0.009670939,0.5943536,0.00004634524,0.0001663634,0.000170235,0.004526933,0.0002344075,0.001174843,0.0002747054,0.00045372,0.05838398],"study_design_scores_gemma":[0.2346171,0.00885249,0.7555746,0.00005728867,0.00002972113,0.00001134131,0.0001162159,0.00003866259,0.00007931422,0.0001735447,0.0003596836,0.0000900234],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9954574,0.0002857129,0.000003627388,0.002257954,0.0002517224,0.0009612534,0.00064087,0.000004703174,0.0001367572],"genre_scores_gemma":[0.9982827,0.0004124288,0.00002421728,0.0008998717,0.00008193007,0.0002141222,0.00005174121,0.0000164003,0.00001659287],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1612211,"threshold_uncertainty_score":0.9984155,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2901506506","doi":"10.1158/2159-8290.cd-18-0715","title":"<i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma","year":2018,"lang":"en","type":"article","venue":"Cancer Discovery","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":432,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre","funders":"Cancer Research UK","keywords":"Reversion; PARP inhibitor; Cancer research; Poly ADP ribose polymerase; Ovarian carcinoma; Mutation; Ovarian cancer; Biology; DNA; Genetics; Medicine; Oncology; Cancer; Polymerase; Gene; Phenotype","retraction":null,"screen_n_in":null,"score":{"opus":0.0169701192130969,"gpt":0.2694381824583575,"spread":0.2524680632452607,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003472445,0.0002252476,0.0003728094,0.0002000382,0.0001648592,0.00006570087,0.0001433874,0.00008431103,0.00005217451],"category_scores_gemma":[0.00008146624,0.0001898845,0.0000558415,0.0007657855,0.0002669751,0.0004281023,0.00008076851,0.0002067444,0.000008684571],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000972196,"about_ca_system_score_gemma":0.0005263136,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000740278,"about_ca_topic_score_gemma":0.002304687,"domain_scores_codex":[0.9980623,0.0001216652,0.0004882615,0.0005524191,0.000366818,0.0004085647],"domain_scores_gemma":[0.9990439,0.0001291416,0.0001501086,0.0004625113,0.00007592165,0.0001383763],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.003877756,0.0004195191,0.6981724,0.0008013789,0.0001148213,0.0003392977,0.01247497,0.0004091617,0.2359655,0.001513962,0.04331727,0.002593971],"study_design_scores_gemma":[0.006049385,0.0002057353,0.9561715,0.002086363,0.00006571733,0.00003249945,0.0007882153,0.0001676429,0.02584973,0.0006838599,0.00752433,0.0003750504],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9872441,0.001526043,0.0002510815,0.008113303,0.0006780523,0.0009960192,0.0001525597,0.00004105384,0.0009977362],"genre_scores_gemma":[0.9928479,0.0001032612,0.0004297368,0.004604749,0.001021474,0.0003865064,0.00005334121,0.00004086262,0.0005121616],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2579991,"threshold_uncertainty_score":0.7743264,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2810583998","doi":"10.1038/s41586-018-0291-z","title":"CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions","year":2018,"lang":"en","type":"article","venue":"Nature","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":418,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Canadian Institute for Advanced Research; University of Toronto; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"National Cancer Institute; Medical Research Council; U.S. Department of Defense; European Commission; Prostate Cancer Foundation; Movember Foundation; Prostate Cancer UK; Canadian Institutes of Health Research; National Science Foundation; Cancer Research UK; Krembil Foundation; Stand Up To Cancer; Blood Cancer UK; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung","keywords":"DNA repair; Olaparib; CRISPR; Biology; PARP1; Poly ADP ribose polymerase; PARP inhibitor; Gene; Genome instability; Molecular biology; Polymerase; Cancer research; DNA damage; DNA; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.02277558244706928,"gpt":0.3584049899763154,"spread":0.3356294075292461,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002004866,0.0001456528,0.0002736585,0.0001594481,0.0001212793,0.00001355584,0.0001450015,0.0006411701,0.0007267866],"category_scores_gemma":[0.0001417562,0.0001312875,0.0001418675,0.0002855166,0.0002395765,0.00006916813,0.00004324271,0.0011503,0.0001784328],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007701664,"about_ca_system_score_gemma":0.0001274672,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008938377,"about_ca_topic_score_gemma":0.00003184522,"domain_scores_codex":[0.9988481,0.00004018865,0.0002688266,0.0002730143,0.0003248818,0.0002449574],"domain_scores_gemma":[0.9989843,0.00006627063,0.0001353107,0.0004117076,0.0002767993,0.0001255825],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0005504886,0.0001651662,0.008555801,0.0001372535,0.0002388983,0.00003175033,0.001386994,0.000007827788,0.8447993,0.001439722,0.1360019,0.006684875],"study_design_scores_gemma":[0.003997896,0.0006241324,0.1512986,0.001014334,0.0002143015,0.0002486724,0.0008292272,0.0001431362,0.4380814,0.002184091,0.4009661,0.0003980387],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9790756,0.002443865,0.0009914818,0.004393061,0.0004321689,0.0003505534,0.00002004914,0.0001280584,0.01216517],"genre_scores_gemma":[0.9904498,0.0001193702,0.001272702,0.00563387,0.0008426563,0.000009916943,0.00001523781,0.00003677355,0.001619711],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4067179,"threshold_uncertainty_score":0.7957803,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2623263876","doi":"10.1158/2159-8290.cd-17-0419","title":"Secondary Somatic Mutations Restoring <i>RAD51C</i> and <i>RAD51D</i> Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma","year":2017,"lang":"en","type":"article","venue":"Cancer Discovery","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":417,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency","funders":"National Institute of Environmental Health Sciences; National Cancer Institute; National Institute of General Medical Sciences; Cancer Research UK","keywords":"Cancer research; PARP inhibitor; Germline mutation; Biology; Olaparib; Mutation; Medicine; Genetics; Gene; Poly ADP ribose polymerase; Polymerase","retraction":null,"screen_n_in":null,"score":{"opus":0.02426957560772021,"gpt":0.284101260368508,"spread":0.2598316847607878,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003365617,0.000301475,0.0004984154,0.0001236893,0.0006373344,0.0003075854,0.0002881013,0.0001142705,0.00004657413],"category_scores_gemma":[0.000164466,0.0002299997,0.0000663863,0.0002512242,0.0003427292,0.0007408127,0.0000896393,0.0003075131,0.000006564567],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007709692,"about_ca_system_score_gemma":0.000744751,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008509278,"about_ca_topic_score_gemma":0.008837909,"domain_scores_codex":[0.9979726,0.0001051143,0.0004280268,0.000558418,0.0004508699,0.0004849767],"domain_scores_gemma":[0.9982985,0.0001851209,0.0003466656,0.0008855669,0.00008295693,0.0002012311],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.002780089,0.0004678702,0.9278662,0.0005917272,0.0005615443,0.0003755929,0.008486041,0.0006873509,0.02768918,0.003430985,0.02482936,0.002234087],"study_design_scores_gemma":[0.007243521,0.000177793,0.9713956,0.002036946,0.0001592157,0.00002035807,0.000464333,0.00006109697,0.011943,0.0009909102,0.005070318,0.0004369675],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9785051,0.001589546,0.000133726,0.01638944,0.0006201538,0.0009476041,0.0002634716,0.00006098675,0.001489958],"genre_scores_gemma":[0.9941635,0.0001356488,0.0003425545,0.001900051,0.0005467574,0.0006697426,0.00004269572,0.00006523703,0.002133803],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04352937,"threshold_uncertainty_score":0.9379116,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4236289131","doi":"10.1016/s1470-2045(21)00073-5","title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":416,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"Merck; AstraZeneca","keywords":"Olaparib; Medicine; BRCA mutation; Internal medicine; Clinical endpoint; Ovarian cancer; Oncology; Placebo; Progression-free survival; PARP inhibitor; Randomized controlled trial; Cancer; Chemotherapy; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.05218418572592092,"gpt":0.3670435714528127,"spread":0.3148593857268918,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001287344,0.0002802238,0.002061547,0.0003138432,0.0001008636,0.00002252634,0.000114421,0.0002185501,0.0003291141],"category_scores_gemma":[0.0002410898,0.000184655,0.0001777709,0.001153883,0.0002892345,0.00009859209,0.00002881849,0.0004792101,0.000003148457],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003670827,"about_ca_system_score_gemma":0.0009201419,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000499985,"about_ca_topic_score_gemma":0.00124039,"domain_scores_codex":[0.9971963,0.0007050096,0.0007692005,0.0004976022,0.0003881238,0.0004438325],"domain_scores_gemma":[0.9971926,0.001058625,0.0006860362,0.0004408003,0.000522828,0.00009906299],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9821005,0.001081023,0.002179453,0.00002202355,0.003164578,0.0001772732,0.002687767,0.0005248552,0.001478194,0.0003591828,0.0002748874,0.005950271],"study_design_scores_gemma":[0.9836938,0.00415537,0.006467306,0.0001378844,0.001342671,0.00004474492,0.0003035956,0.00110283,0.001685781,0.0001329979,0.0007358519,0.0001971319],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9885744,0.0003609026,0.0002793561,0.004746426,0.0002231716,0.003907245,0.0001127913,0.00002938351,0.001766298],"genre_scores_gemma":[0.9944612,0.0005291211,0.0004399485,0.002406079,0.0003057439,0.001345311,0.0001878175,0.00002857634,0.0002961392],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005886838,"threshold_uncertainty_score":0.7530012,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2164708087","doi":"10.1093/nar/gkn771","title":"Proteome-wide identification of poly(ADP-ribose) binding proteins and poly(ADP-ribose)-associated protein complexes","year":2008,"lang":"en","type":"article","venue":"Nucleic Acids Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":415,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Université Laval; Centre hospitalier de l'Université Laval; University of Alberta","funders":"National Institute of Neurological Disorders and Stroke; U.S. Public Health Service; Canadian Institutes of Health Research; Centre National de la Recherche Scientifique","keywords":"Proteome; Biology; Poly ADP ribose polymerase; Biochemistry; Ribose; Proteomics; Plasma protein binding; In silico; Enzyme; Computational biology; Polymerase; Gene","retraction":null,"screen_n_in":null,"score":{"opus":0.08688888882635037,"gpt":0.3708946421512399,"spread":0.2840057533248895,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002508068,0.0003358045,0.0006855691,0.0009496584,0.0007724726,0.00008087637,0.0004041682,0.0003461323,0.0004418182],"category_scores_gemma":[0.001478628,0.0003229284,0.0001501526,0.001692035,0.001331185,0.0003599471,0.00021705,0.001075124,0.0001769033],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006639524,"about_ca_system_score_gemma":0.0006206131,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004591199,"about_ca_topic_score_gemma":0.00001910049,"domain_scores_codex":[0.9944533,0.0006153575,0.0009741405,0.0007866499,0.002172281,0.0009982615],"domain_scores_gemma":[0.9970481,0.0002468248,0.0003883742,0.0008579677,0.001065774,0.0003929865],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0006742025,0.0005473777,0.02413368,0.0003448892,0.0001487187,0.00005716209,0.001465338,4.943118e-7,0.9667408,0.0002793369,0.002878628,0.002729332],"study_design_scores_gemma":[0.004426866,0.001182916,0.1173365,0.0008822759,0.00002857035,0.00009265089,0.0005488395,0.000220343,0.8689693,0.0008148256,0.005124582,0.0003723595],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9865625,0.0008664589,0.0004087603,0.005284157,0.0000916041,0.00488574,0.0001454363,0.0001976222,0.001557716],"genre_scores_gemma":[0.9910846,0.0001743925,0.001533123,0.00009820711,0.0003789788,0.0009040619,0.0001075427,0.0001095503,0.005609567],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09777153,"threshold_uncertainty_score":0.9999223,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1992476369","doi":"10.1016/s0301-472x(03)00083-3","title":"PARP-1, a determinant of cell survival in response to DNA damage","year":2003,"lang":"en","type":"review","venue":"Experimental Hematology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":391,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Université Laval","funders":"Canadian Institutes of Health Research","keywords":"Poly ADP ribose polymerase; DNA damage; DNA repair; Biology; Genome instability; DNA; Apoptosis; Polymerase; Cell biology; DNA replication; Cancer research; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.06411873971903466,"gpt":0.4195844937348274,"spread":0.3554657540157927,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004462544,0.0004454625,0.002877347,0.0005147064,0.0000249456,0.000005800351,0.0002008746,0.0004033604,0.000612815],"category_scores_gemma":[0.00004234126,0.0003959806,0.0003636472,0.0004248078,0.0001508661,0.00003698179,0.0000876217,0.000313163,0.0002521071],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004377309,"about_ca_system_score_gemma":0.0004603369,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001345715,"about_ca_topic_score_gemma":0.00000510169,"domain_scores_codex":[0.9969275,0.0007619696,0.001076997,0.0005546989,0.0002490598,0.0004297592],"domain_scores_gemma":[0.9984607,0.0003236696,0.000330974,0.0006571553,0.00003156591,0.0001960061],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.05316616,0.03568868,0.001205384,0.2508011,0.002183705,0.04053795,0.02589626,0.000002384097,0.2289866,0.02506272,0.03598451,0.3004845],"study_design_scores_gemma":[0.002240082,0.0008609947,0.000008320777,0.00820931,0.00008390495,0.001204204,0.0003667572,4.764841e-7,0.137947,0.000006998625,0.8486777,0.0003942708],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.009490502,0.9858976,0.00001011693,0.00003009245,0.0005536337,0.001401803,0.00004239873,0.0000267371,0.00254711],"genre_scores_gemma":[0.01080936,0.9846786,0.001537744,0.0003336416,0.00007618652,0.001099659,0.00007825365,0.0001655429,0.00122102],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.8126932,"threshold_uncertainty_score":0.9998492,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4281666355","doi":"10.1200/jco.22.01003","title":"A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45)","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":384,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université de Sherbrooke","funders":"National Cancer Institute; Genentech; Eisai; National Institute for Health and Care Research; MacroGenics; Clovis Oncology; NuCana; Novocure; Puma Biotechnology; Regeneron Pharmaceuticals; Array BioPharma; EMD Serono; Mersana Therapeutics; Karyopharm Therapeutics; Eli Lilly and Company; AstraZeneca; American Society of Clinical Oncology; Amgen; Pfizer","keywords":"Medicine; Population; Hazard ratio; Internal medicine; Ovarian cancer; Clinical endpoint; Placebo; Oncology; BRCA mutation; Surgery; Cancer; Clinical trial; Confidence interval; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.1037382995368031,"gpt":0.4865092343933121,"spread":0.382770934856509,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.006626099,0.0003539748,0.003734326,0.0003637922,0.0001200431,0.000017756,0.0003000996,0.0002324909,0.002344241],"category_scores_gemma":[0.001610801,0.0002319712,0.0008287961,0.0004455168,0.000246237,0.0001278383,0.00005041501,0.001167525,0.00001700017],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002277472,"about_ca_system_score_gemma":0.0050729,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000775651,"about_ca_topic_score_gemma":0.0002051313,"domain_scores_codex":[0.991651,0.002605872,0.0037346,0.0004844511,0.001004908,0.0005191932],"domain_scores_gemma":[0.992348,0.003370813,0.002686708,0.0004091932,0.000523543,0.0006617922],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8868774,0.01075961,0.004140001,0.000004653581,0.001083628,0.0005454744,0.001228782,0.001135322,0.00002710477,0.00009323227,0.003099129,0.09100565],"study_design_scores_gemma":[0.8412972,0.07603286,0.002679373,0.0001130988,0.0004875579,0.00004606901,0.0001462507,0.0002081003,0.00003457932,0.0004500529,0.07829754,0.0002073327],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9725434,0.0004131105,0.0006040084,0.01882882,0.002665017,0.004083162,0.00004043208,0.00001880558,0.0008032287],"genre_scores_gemma":[0.9750015,0.001616196,0.002181466,0.01681982,0.001918686,0.001688972,0.00001449405,0.00007036678,0.0006885434],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09079832,"threshold_uncertainty_score":0.9985678,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3208204329","doi":"10.1016/s1470-2045(21)00531-3","title":"Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":371,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"Merck Sharp and Dohme; AstraZeneca","keywords":"Olaparib; Ovarian cancer; Mutation; BRCA mutation; Clinical trial; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.04020537618833177,"gpt":0.3627496910676291,"spread":0.3225443148792974,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007843681,0.0002599524,0.001510255,0.00008355598,0.0001332845,0.0000202463,0.0001407906,0.0001823546,0.0001804042],"category_scores_gemma":[0.000561215,0.0001714105,0.0001845172,0.0002604977,0.0002413867,0.0001126474,0.00003149952,0.0002705628,0.000002972253],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002609744,"about_ca_system_score_gemma":0.0008816245,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00006928024,"about_ca_topic_score_gemma":0.0004235298,"domain_scores_codex":[0.9978985,0.000273431,0.0006334309,0.0004446194,0.0002879424,0.0004620762],"domain_scores_gemma":[0.996686,0.001536077,0.0006005306,0.0004287605,0.0006228616,0.0001258171],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9824301,0.0007580012,0.0002322737,0.0001031185,0.0006267845,0.00003707406,0.0009652442,0.0001078967,0.001484477,0.001094629,0.002220097,0.009940309],"study_design_scores_gemma":[0.9838487,0.004956414,0.0001805291,0.0001975246,0.0005985782,0.00002584403,0.0002530597,0.0002515088,0.001345581,0.0007785377,0.007372088,0.0001916186],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9805338,0.0005822497,0.003058075,0.005115569,0.001024718,0.008479343,0.0002058085,0.00005218987,0.0009482898],"genre_scores_gemma":[0.9856749,0.0005321234,0.003514387,0.001994689,0.0008555947,0.00648051,0.0001943146,0.00005345868,0.0007000906],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009748691,"threshold_uncertainty_score":0.6989917,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1975272351","doi":"10.1016/j.molcel.2008.08.009","title":"Substrate-Assisted Catalysis by PARP10 Limits Its Activity to Mono-ADP-Ribosylation","year":2008,"lang":"en","type":"article","venue":"Molecular Cell","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":353,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Western University","funders":"","keywords":"Polymerase; Biology; ADP-ribosylation; Poly ADP ribose polymerase; Biochemistry; Transferase; Enzyme; Residue (chemistry); PARP1; DNA repair; DNA; NAD+ kinase","retraction":null,"screen_n_in":null,"score":{"opus":0.03108811992052445,"gpt":0.2788114898314135,"spread":0.247723369910889,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000105089,0.0002224865,0.0003123966,0.000135638,0.0001162814,0.00001692512,0.0001030217,0.0001428944,0.0001828803],"category_scores_gemma":[0.00002111351,0.000234717,0.0001533242,0.0005219394,0.00003973738,0.00009476083,0.00001930366,0.0001974651,0.0003841764],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001928353,"about_ca_system_score_gemma":0.0001112146,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00006788524,"about_ca_topic_score_gemma":0.000009131289,"domain_scores_codex":[0.9984835,0.00007799279,0.0002405313,0.0004415486,0.0004347928,0.0003216507],"domain_scores_gemma":[0.9989597,0.00002617393,0.0001049948,0.000469845,0.0001516944,0.0002875877],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.00021783,0.0003154374,0.001879808,0.00003146034,0.00005487445,0.000179481,0.0001887674,0.0001156895,0.9891174,0.000006792477,0.00635731,0.001535109],"study_design_scores_gemma":[0.00170109,0.0001958185,0.01462593,0.00002522559,0.00007049466,0.00003613882,0.00001141586,0.0001801675,0.9710125,0.000006433325,0.01190329,0.0002314773],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.981917,0.0005739286,0.006042414,0.001318824,0.0001021467,0.0004789097,0.0000281627,0.0001188528,0.009419732],"genre_scores_gemma":[0.9956251,0.0000995364,0.0004442396,0.001183775,0.00005409073,0.00008350919,0.0001549702,0.00004827762,0.002306538],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01810492,"threshold_uncertainty_score":0.9571481,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2888493183","doi":"10.1016/j.dnarep.2018.08.022","title":"The comings and goings of PARP-1 in response to DNA damage","year":2018,"lang":"en","type":"review","venue":"DNA repair","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":342,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Poly ADP ribose polymerase; Biology; DNA damage; DNA repair; Chromatin; DNA; Polymerase; Cell biology; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.04573360199352177,"gpt":0.3756352712475349,"spread":0.3299016692540131,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002022471,0.0002675547,0.001166067,0.0002296497,0.00006570119,0.00001790186,0.0001686041,0.0002073011,0.00004514026],"category_scores_gemma":[0.0007618827,0.0001770868,0.0002585174,0.000512096,0.0002710882,0.00003975949,0.0000957497,0.0002903641,0.00005783093],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002174033,"about_ca_system_score_gemma":0.0003811688,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002471952,"about_ca_topic_score_gemma":0.00002008981,"domain_scores_codex":[0.997978,0.0003843732,0.000725588,0.0003897891,0.0002634208,0.0002588515],"domain_scores_gemma":[0.9976586,0.001011814,0.000302272,0.0007847145,0.0001097599,0.0001328397],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.006622665,0.0002992728,0.0003273082,0.03128608,0.000765665,0.0003393608,0.003780721,8.788142e-8,0.0009119254,0.0005127736,0.2743355,0.6808187],"study_design_scores_gemma":[0.000634325,0.000338782,0.0002356144,0.0170344,0.0001329198,0.00006202362,0.00005109042,0.000001845484,0.00007387014,0.00003203193,0.981245,0.0001581169],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.01159062,0.9848228,0.000002558312,0.0008179718,0.0001845433,0.001240885,0.00003742385,0.00008440733,0.001218814],"genre_scores_gemma":[0.0001357034,0.9962292,0.0003485492,0.0005537972,0.0001612352,0.0001871662,0.00001427347,0.0000569694,0.002313105],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.7069095,"threshold_uncertainty_score":0.7221389,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2085908746","doi":"10.1038/sj.cdd.4400851","title":"Characterization of the necrotic cleavage of poly(ADP-ribose) polymerase (PARP-1): implication of lysosomal proteases","year":2001,"lang":"en","type":"article","venue":"Cell Death and Differentiation","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":338,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Université Laval","funders":"Medical Research Council; Natural Sciences and Engineering Research Council of Canada","keywords":"Poly ADP ribose polymerase; Proteases; Caspase; Jurkat cells; Cathepsin; Cleavage (geology); Apoptosis; Molecular biology; Biology; Programmed cell death; Cytosol; Biochemistry; Polymerase; Cell biology; Enzyme; T cell; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.01573362775224625,"gpt":0.2491917566021433,"spread":0.2334581288498971,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005665157,0.0001003154,0.0002142618,0.00008646394,0.00004256793,0.000005374837,0.00005307178,0.00006752451,0.00005425842],"category_scores_gemma":[0.00002138357,0.00007580462,0.00007323307,0.0001743323,0.00006230397,0.00008277485,0.00001819359,0.00005343583,9.164801e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002307012,"about_ca_system_score_gemma":0.00005097614,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005198182,"about_ca_topic_score_gemma":0.000001569424,"domain_scores_codex":[0.9991401,0.00005072172,0.0003673855,0.0001457048,0.0001940243,0.0001020755],"domain_scores_gemma":[0.9991259,0.00002472895,0.0004317099,0.0002562458,0.0001099658,0.00005144478],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0002327743,0.0002126341,0.1587223,0.0001883704,0.00001531392,1.715617e-7,0.0001679099,3.464409e-7,0.8376195,0.0002340974,0.000008289991,0.002598243],"study_design_scores_gemma":[0.0008271798,0.00008819898,0.4504627,0.00007688952,0.00005491152,0.000003703494,0.00001406526,0.00009122893,0.5482274,0.00009413716,0.00002497105,0.00003455896],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9956779,0.0002660815,0.002702378,0.0002126234,0.00007807742,0.0006129444,0.00004321587,0.00001333787,0.0003934414],"genre_scores_gemma":[0.9992567,0.0002030993,0.0000583507,0.0000599848,0.00007566761,0.00002952295,0.0001481894,0.00001162644,0.0001568608],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2917404,"threshold_uncertainty_score":0.3091223,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1997953313","doi":"10.1073/pnas.0406182101","title":"Failure to degrade poly(ADP-ribose) causes increased sensitivity to cytotoxicity and early embryonic lethality","year":2004,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":336,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université Laval","funders":"National Institute of Neurological Disorders and Stroke; National Institutes of Health","keywords":"Poly ADP ribose polymerase; Biology; Embryonic stem cell; DNA damage; Synthetic lethality; Cytotoxicity; DNA repair; Cell biology; Molecular biology; Biochemistry; Polymerase; Enzyme; DNA; In vitro; Gene","retraction":null,"screen_n_in":null,"score":{"opus":0.04450856181625495,"gpt":0.3339432891514686,"spread":0.2894347273352137,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001544085,0.0001318435,0.0002621633,0.0002286793,0.000199763,0.00002660984,0.0002306678,0.00009710586,0.000006956036],"category_scores_gemma":[0.0008711438,0.00009532782,0.00007156446,0.0009929452,0.0006477479,0.0003093904,0.0001124567,0.0002116896,0.000002664568],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001596983,"about_ca_system_score_gemma":0.0001354048,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001829933,"about_ca_topic_score_gemma":0.000002234038,"domain_scores_codex":[0.9979134,0.00001337361,0.0002796818,0.0003454447,0.00123427,0.0002137889],"domain_scores_gemma":[0.9991329,0.0001211898,0.0002174147,0.00001623533,0.0003409131,0.0001713993],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.00008883531,0.000064601,0.02808229,0.00005629942,0.00001976213,5.961755e-8,0.0004725176,0.00002995286,0.9626766,0.007997188,0.0004279172,0.00008401793],"study_design_scores_gemma":[0.0003894201,0.0001115377,0.4191574,0.000187378,0.00001166744,0.00003413573,0.00009426384,0.000006285029,0.5733041,0.006535827,0.00009762203,0.0000703012],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9503453,0.00007438331,0.00001205829,0.048586,0.00001322086,0.0004309961,0.00003836089,0.00002373201,0.000475997],"genre_scores_gemma":[0.9922412,0.000006964705,0.004522351,0.003009677,0.0001527865,0.00001869163,1.117605e-7,0.000006084118,0.00004210306],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3910751,"threshold_uncertainty_score":0.3887356,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3014627414","doi":"10.1126/science.aax6367","title":"Structural basis for allosteric PARP-1 retention on DNA breaks","year":2020,"lang":"en","type":"article","venue":"Science","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":331,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University; Université de Montréal","funders":"National Institute of General Medical Sciences; Canadian Institutes of Health Research; National Institutes of Health; Cancer Research UK; National Cancer Institute; Breast Cancer Now","keywords":"Poly ADP ribose polymerase; Allosteric regulation; DNA; DNA repair; Polymerase; Chemistry; DNA damage; PARP inhibitor; Computational biology; Cancer research; Biochemistry; Biology; Enzyme","retraction":null,"screen_n_in":null,"score":{"opus":0.0836537283378432,"gpt":0.340849481369791,"spread":0.2571957530319479,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001600887,0.0000700309,0.0001022811,0.00004994606,0.0001291414,0.00002823107,0.0001239892,0.00002341936,0.0001646294],"category_scores_gemma":[0.0001514887,0.00005679131,0.00005054995,0.0004110776,0.0002129303,0.0001358717,0.00001866752,0.00006130313,0.00004393739],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00008987395,"about_ca_system_score_gemma":0.0001213597,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000002081252,"about_ca_topic_score_gemma":5.145228e-7,"domain_scores_codex":[0.9990384,0.000009177323,0.0001186613,0.0003004042,0.0003397107,0.000193676],"domain_scores_gemma":[0.9995188,0.00002843789,0.00004886935,0.0001563439,0.00009370369,0.0001538562],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0004949858,0.00001449931,0.001240688,0.00005482011,0.000008106406,0.000004563809,0.0006911863,0.00002130276,0.9742792,0.0008210009,0.002368583,0.02000106],"study_design_scores_gemma":[0.004971683,0.00356495,0.169154,0.0003220361,0.00006219657,0.00007588471,0.0004120265,0.01252341,0.7647396,0.002242559,0.04143658,0.0004950576],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.983434,0.00004327405,0.0007441362,0.01258548,0.0004191373,0.0003922067,0.00002350641,0.00007229826,0.002286022],"genre_scores_gemma":[0.9914244,0.000006503341,0.001386005,0.006764452,0.000226328,0.00002566493,0.00000527157,0.000007218332,0.000154153],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2095396,"threshold_uncertainty_score":0.2315882,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3183970717","doi":"10.1111/febs.16142","title":"ADP‐ribosyltransferases, an update on function and nomenclature","year":2021,"lang":"en","type":"article","venue":"FEBS Journal","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":327,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal; Institute of Cancer Research; Université Laval","funders":"National Institute of General Medical Sciences; National Heart, Lung, and Blood Institute; Cancer Research UK; National Institutes of Health; RWTH Aachen University; Deutsche Forschungsgemeinschaft; Wellcome Trust","keywords":"Nomenclature; Function (biology); Computational biology; Chemistry; Biology; Genetics; Zoology; Taxonomy (biology)","retraction":null,"screen_n_in":null,"score":{"opus":0.02064099260354682,"gpt":0.2970770958095009,"spread":0.2764361032059541,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001536982,0.0001032104,0.0001553404,0.00007713823,0.0001473312,0.00006281924,0.00002877446,0.00008079155,0.002003592],"category_scores_gemma":[0.00001569304,0.00008755794,0.00005584001,0.0001217211,0.00003014528,0.0001616282,0.000004945268,0.0005143538,0.00003462284],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007818016,"about_ca_system_score_gemma":0.0001404554,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000001094915,"about_ca_topic_score_gemma":0.00000410105,"domain_scores_codex":[0.9991876,0.00006444517,0.0001719556,0.0001690422,0.0002446462,0.0001622976],"domain_scores_gemma":[0.9994202,0.00001775361,0.00004302071,0.0001528344,0.0001287621,0.0002374177],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","study_design_scores_codex":[0.009660987,0.001846532,0.03780548,0.0002049752,0.0009272678,0.003562945,0.001585356,0.0001264472,0.6761573,0.01238114,0.1018031,0.1539385],"study_design_scores_gemma":[0.01947504,0.004910478,0.2456017,0.001002598,0.0003943778,0.02062023,0.0005719843,0.0001458005,0.08276809,0.02476218,0.5990562,0.000691317],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9821258,0.002410518,0.003173348,0.00800465,0.0009255484,0.00009199875,0.00002225583,0.00004460286,0.003201337],"genre_scores_gemma":[0.9878801,0.001448994,0.000877743,0.007731661,0.001437252,0.000003954437,0.00004895325,0.00002185197,0.0005495215],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5933892,"threshold_uncertainty_score":0.9989087,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1993972255","doi":"10.1006/excr.2001.5263","title":"Importance of Poly(ADP-Ribose) Glycohydrolase in the Control of Poly(ADP-Ribose) Metabolism","year":2001,"lang":"en","type":"review","venue":"Experimental Cell Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":327,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université Laval","funders":"","keywords":"Poly ADP ribose polymerase; Biology; Polymerase; Biochemistry; Ribose; Enzyme; ADP-ribosylation; DNA repair; RNA polymerase III; DNA; Chromatin; Cytoplasm; Cell biology; NAD+ kinase","retraction":null,"screen_n_in":null,"score":{"opus":0.126349552235156,"gpt":0.4686902832341981,"spread":0.3423407309990421,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003353645,0.0007444739,0.003210423,0.001151779,0.0001465424,0.00004279116,0.001217806,0.0005068938,0.001657989],"category_scores_gemma":[0.0001348036,0.0005349018,0.001001615,0.002295426,0.001014549,0.0001506617,0.0002158032,0.002003381,0.0001280472],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007405549,"about_ca_system_score_gemma":0.001298156,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006703047,"about_ca_topic_score_gemma":0.00001167409,"domain_scores_codex":[0.9911162,0.001803249,0.002013783,0.0009780668,0.002863654,0.001225107],"domain_scores_gemma":[0.9956223,0.001081879,0.0007868408,0.001853046,0.0003069764,0.000348955],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.009825098,0.02149252,0.0008846101,0.05143754,0.002939932,0.003905992,0.01148067,0.000004036176,0.1664236,0.003307106,0.04833617,0.6799628],"study_design_scores_gemma":[0.005865684,0.0008537049,0.00003036922,0.005064343,0.0002250397,0.0001800454,0.0009283738,0.00001208414,0.07154649,0.00005461059,0.9147842,0.0004550768],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.001783439,0.9796945,0.00001685296,0.0003047948,0.0003276398,0.003777712,0.0003050349,0.00002988932,0.01376018],"genre_scores_gemma":[0.05698051,0.9383073,0.0001401687,0.0002462222,0.001195461,0.001134285,0.000198663,0.0001671653,0.001630224],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.866448,"threshold_uncertainty_score":0.9997103,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3081315565","doi":"10.1016/s1470-2045(20)30447-2","title":"Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":321,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Cancer Institute; AstraZeneca; Invitae; PharmaMar; Eisai; Pfizer","keywords":"Veliparib; Carboplatin; Oncology; Medicine; Placebo; Breast cancer; Internal medicine; BRCA mutation; Paclitaxel; Cancer; Chemotherapy; Biology; Genetics; Alternative medicine; Poly ADP ribose polymerase; Cisplatin; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.07829391178294297,"gpt":0.3971052690556947,"spread":0.3188113572727517,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007306079,0.0003157408,0.001703268,0.00009657546,0.00009438824,0.00002350302,0.0001779365,0.0002063056,0.0003060605],"category_scores_gemma":[0.00009055214,0.000198042,0.00009749698,0.000438664,0.0003055,0.00009982499,0.00004173023,0.0007335902,0.00001488945],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003013202,"about_ca_system_score_gemma":0.0006606851,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001992306,"about_ca_topic_score_gemma":0.0004122219,"domain_scores_codex":[0.9976404,0.0004130554,0.0006279975,0.0004898752,0.00028578,0.0005428825],"domain_scores_gemma":[0.9983895,0.0005979164,0.000342528,0.0003104323,0.0001119687,0.0002476714],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9814091,0.000290731,0.0002815467,0.00006283411,0.0003294003,0.0001338397,0.001849537,0.0002994212,0.006771091,0.0001069876,0.001301746,0.007163808],"study_design_scores_gemma":[0.9863515,0.002965583,0.0001984456,0.0001257379,0.0002808673,0.0002335109,0.0003802267,0.001175484,0.0008084486,0.00006856104,0.00717814,0.000233481],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9326614,0.00150152,0.0001431169,0.05608265,0.0002744309,0.006016455,0.0001025771,0.0001193509,0.003098458],"genre_scores_gemma":[0.9857097,0.0007828597,0.0002868385,0.008336835,0.001709661,0.002952509,0.00003386688,0.000048618,0.000139081],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05304829,"threshold_uncertainty_score":0.8075917,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2095061901","doi":"10.1073/pnas.1405158111","title":"Poly(ADP-ribose) polymerase-dependent energy depletion occurs through inhibition of glycolysis","year":2014,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":313,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Université Laval","funders":"National Institute of Neurological Disorders and Stroke; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute on Drug Abuse; Canadian Institutes of Health Research","keywords":"Poly ADP ribose polymerase; NAD+ kinase; Hexokinase; Glycolysis; Programmed cell death; Polymerase; Ribose; Cell biology; Bioenergetics; Biology; Enzyme; Biochemistry; Chemistry; Mitochondrion; Apoptosis","retraction":null,"screen_n_in":null,"score":{"opus":0.03861303175714018,"gpt":0.3213103621072992,"spread":0.282697330350159,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001026577,0.0001291788,0.0002902021,0.0002436118,0.0001458676,0.00001152559,0.0003008541,0.0001245413,0.00006570137],"category_scores_gemma":[0.0003311224,0.00009391582,0.0001540526,0.0009274363,0.0009061575,0.0004363748,0.00006820764,0.0001413851,0.000001486786],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00008854888,"about_ca_system_score_gemma":0.00006588505,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00006143319,"about_ca_topic_score_gemma":2.229572e-7,"domain_scores_codex":[0.9971501,0.00001643291,0.0005517055,0.000290605,0.00181554,0.0001756083],"domain_scores_gemma":[0.9985397,0.0001237418,0.0008066575,0.00001854122,0.0004630607,0.00004823332],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0001365489,0.0001359499,0.004197418,0.0001033897,0.00003994993,8.481953e-9,0.000216912,0.00002448724,0.9075613,0.08466353,0.001407725,0.001512762],"study_design_scores_gemma":[0.0007892205,0.000173553,0.0104696,0.0002837336,0.00004310978,0.00001808732,0.0001403827,0.0003620448,0.9500857,0.03672966,0.0008155762,0.000089359],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9709858,0.000748852,0.0001638923,0.01277993,0.00007514263,0.000244379,0.00004554443,0.00003636318,0.01492012],"genre_scores_gemma":[0.9966711,0.0001026184,0.00136368,0.00142386,0.0002623122,0.00002113926,0.00000106807,0.000008294734,0.000145889],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04793387,"threshold_uncertainty_score":0.3829776,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2079891276","doi":"10.1016/j.molcel.2010.12.006","title":"PARP-3 and APLF Function Together to Accelerate Nonhomologous End-Joining","year":2011,"lang":"en","type":"article","venue":"Molecular Cell","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":311,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Centre hospitalier universitaire de Québec","funders":"Biotechnology and Biological Sciences Research Council; Cancer Research UK","keywords":"DNA ligase; Biology; DNA repair protein XRCC4; Non-homologous end joining; DNA repair; Ku80; Chromatin; DNA; Molecular biology; Poly ADP ribose polymerase; Sticky and blunt ends; Genetics; Cell biology; DNA-binding protein; DNA mismatch repair; Polymerase; Gene; Transcription factor","retraction":null,"screen_n_in":null,"score":{"opus":0.03390383084429662,"gpt":0.2578351082772855,"spread":0.2239312774329888,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001344037,0.0001442141,0.0001787273,0.0000947084,0.00004954842,0.0000142529,0.00005062318,0.00008935007,0.001098277],"category_scores_gemma":[0.000009693143,0.0001370755,0.00005203578,0.0001358496,0.00004019263,0.00004148241,0.00003544343,0.0001402741,0.0002282759],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004023662,"about_ca_system_score_gemma":0.00003762317,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000471102,"about_ca_topic_score_gemma":0.000003245477,"domain_scores_codex":[0.9990957,0.00004483991,0.0001659744,0.0003011262,0.0001567665,0.0002355429],"domain_scores_gemma":[0.9994394,0.0000107685,0.00004790622,0.0002712993,0.00005850579,0.0001721361],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0009361675,0.0001951955,0.005578613,0.00007753171,0.00009141867,0.0004715314,0.002497157,0.00001372728,0.9702522,0.0004015301,0.003566339,0.01591866],"study_design_scores_gemma":[0.002972572,0.001081386,0.006918329,0.00006968303,0.00009978691,0.00008793207,0.0001601778,0.00004642305,0.9315532,0.0007208274,0.05598604,0.0003035934],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8790907,0.0006698149,0.01726583,0.0003914418,0.0002498331,0.0003696802,0.000003808359,0.0001012292,0.1018577],"genre_scores_gemma":[0.9866499,0.00002915604,0.003630476,0.008296939,0.00007626929,0.00005456732,0.000008543838,0.00004039886,0.001213748],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1075593,"threshold_uncertainty_score":0.9998149,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1959879209","doi":"10.1242/jcs.114.20.3771","title":"Gain-of-function of poly(ADP-ribose) polymerase-1 upon cleavage by apoptotic proteases: implications for apoptosis","year":2001,"lang":"en","type":"article","venue":"Journal of Cell Science","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":286,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université Laval","funders":"","keywords":"Poly ADP ribose polymerase; Biology; Apoptosis; DNA damage; Polymerase; Proteases; PARP1; NAD+ kinase; Caspase; DNA; DNA repair; Molecular biology; Programmed cell death; Cell biology; Biochemistry; Enzyme","retraction":null,"screen_n_in":null,"score":{"opus":0.02564871356309783,"gpt":0.3188024015278726,"spread":0.2931536879647748,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008375701,0.0001138932,0.0003114234,0.0003180872,0.0001315467,0.00001714368,0.0002607392,0.00005373916,0.00007559864],"category_scores_gemma":[0.0001564166,0.0000944269,0.0001730568,0.0008392476,0.000312213,0.000324283,0.0000174777,0.0001463224,0.00000252148],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001644006,"about_ca_system_score_gemma":0.0005510676,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001445335,"about_ca_topic_score_gemma":4.653535e-7,"domain_scores_codex":[0.9983204,0.00003186858,0.0006712373,0.0001832605,0.0005323789,0.0002608283],"domain_scores_gemma":[0.9978902,0.0001246156,0.0008973405,0.0002759346,0.0005923421,0.0002195358],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0004870542,0.000344325,0.001004184,0.00006249086,0.0000163198,3.758812e-7,0.0001130705,0.00002057728,0.9888998,0.0001195638,0.003490867,0.005441376],"study_design_scores_gemma":[0.001759464,0.001457752,0.002827006,0.0001785652,0.00009008908,0.00005594213,0.0001595963,0.0001048588,0.9892132,0.0004701257,0.003593763,0.00008966366],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9301192,0.001426918,0.06048764,0.00423205,0.0004430139,0.0007653583,0.00004356411,0.00001489697,0.002467379],"genre_scores_gemma":[0.9959762,0.0002259487,0.002932235,0.0003245243,0.0002264487,0.00001965125,0.000002799211,0.00001308073,0.0002791838],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06585695,"threshold_uncertainty_score":0.3850617,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2751912349","doi":"10.1016/j.ygyno.2017.08.022","title":"Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2","year":2017,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":278,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency; Centre Hospitalier de l’Université de Montréal; University Health Network; Princess Margaret Cancer Centre","funders":"National Institute for Health and Care Research; Cancer Research UK; Clovis Oncology","keywords":"Medicine; Germline; Germline mutation; Somatic cell; PARP inhibitor; Poly ADP ribose polymerase; Ovarian carcinoma; Cancer research; Ovarian cancer; Mutation; Oncology; Polymerase; Internal medicine; Cancer; Genetics; Biology; DNA; Gene","retraction":null,"screen_n_in":null,"score":{"opus":0.05371604839042909,"gpt":0.3439074718825645,"spread":0.2901914234921354,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005317951,0.0002117643,0.001129332,0.0001981695,0.0001768533,0.00002391851,0.0002682685,0.0001769788,0.0003778438],"category_scores_gemma":[0.000853436,0.00011652,0.00002999285,0.0003942118,0.0007217288,0.0002177595,0.0003224713,0.0002434198,4.14746e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001479596,"about_ca_system_score_gemma":0.0004511958,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002100852,"about_ca_topic_score_gemma":0.0224104,"domain_scores_codex":[0.9980811,0.0003967883,0.0005587729,0.0005493502,0.0002166386,0.0001973173],"domain_scores_gemma":[0.9969353,0.0010083,0.000826039,0.0009940899,0.0001504677,0.00008578367],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.006735713,0.001775253,0.9839277,0.00005683737,0.0008730626,0.00008523891,0.0008390877,0.000005991156,0.0005368621,0.00001133073,0.00005504689,0.005097878],"study_design_scores_gemma":[0.01710138,0.004118819,0.9751722,0.00006660404,0.001349695,0.00001010044,0.0006479823,0.0009337579,0.0003370376,0.0000634766,0.00007251994,0.000126405],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.996916,0.00005130532,0.0000389549,0.0009989219,0.0001122898,0.001327763,0.0004984688,0.0000120183,0.00004428985],"genre_scores_gemma":[0.998433,0.00003579031,0.001132811,0.0001100396,0.00002846178,0.00004826883,0.0001405725,0.00001148186,0.00005955868],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02030955,"threshold_uncertainty_score":0.9954281,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2625362849","doi":"10.1038/s41467-017-00393-y","title":"Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer","year":2017,"lang":"en","type":"article","venue":"Nature Communications","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":278,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia","funders":"Medical Research Council; Vetenskapsrådet; Cancerfonden; National Institute for Health and Care Research; Academy of Medical Sciences; Cancer Research UK; NIHR Cambridge Biomedical Research Centre; Pain Relief Foundation; AFA Försäkring; Hutchison Whampoa Limited; Wellcome Trust; AstraZeneca; National Cancer Research Institute; Torsten Söderbergs Stiftelse; Public Health Agency; Cancer Research Institute","keywords":"Prostate cancer; Androgen receptor; Androgen deprivation therapy; Synthetic lethality; Cancer research; PARP inhibitor; Poly ADP ribose polymerase; Downregulation and upregulation; Prostate; Medicine; Cancer; Biology; Internal medicine; DNA repair; Genetics; Gene","retraction":null,"screen_n_in":null,"score":{"opus":0.0531525519722865,"gpt":0.3711102333803341,"spread":0.3179576814080475,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008120526,0.0001075892,0.0002472968,0.00004426912,0.00060451,0.00006343539,0.0006017715,0.0001464321,0.00003346553],"category_scores_gemma":[0.0002973505,0.00007554545,0.00005283758,0.00008372463,0.0006057773,0.00009572989,0.0001980775,0.001025662,0.000006196903],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009290542,"about_ca_system_score_gemma":0.0001198203,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003508153,"about_ca_topic_score_gemma":0.0005765654,"domain_scores_codex":[0.9990453,0.0002331815,0.0002339198,0.0001801091,0.000156013,0.000151552],"domain_scores_gemma":[0.9973187,0.0003825083,0.0001618027,0.00195886,0.0001146869,0.00006338579],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001201969,0.0004108511,0.8851793,0.0002070031,0.0005751969,0.000009136278,0.009309393,0.00004326032,0.007687643,0.0296431,0.003187323,0.06254587],"study_design_scores_gemma":[0.02844892,0.0001873577,0.2990398,0.003319246,0.0004483443,0.00005838821,0.001138771,0.004083834,0.02420846,0.01840486,0.6194958,0.001166215],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.7449632,0.071672,0.00003602461,0.1751932,0.0001934257,0.00157723,0.0002211195,0.00007544814,0.006068374],"genre_scores_gemma":[0.9869291,0.01139359,0.0004991681,0.0006108129,0.00009231643,0.0002929588,0.00003684994,0.00001608158,0.0001291795],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6163085,"threshold_uncertainty_score":0.4649463,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2898861270","doi":"10.15252/emmm.201809172","title":"A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation","year":2018,"lang":"en","type":"article","venue":"EMBO Molecular Medicine","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":274,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Dalhousie University; Université Laval; Centre hospitalier de l'Université Laval","funders":"Instituto de Salud Carlos III; European Society for Medical Oncology; Canadian HIV Trials Network, Canadian Institutes of Health Research; National Cancer Institute; Agència de Gestió d'Ajuts Universitaris i de Recerca; Cancer Research UK; Generalitat de Catalunya; Fundación Científica Asociación Española Contra el Cáncer; Fundación Cellex; AstraZeneca","keywords":"Mutation; Molecular biology; Poly ADP ribose polymerase; Chemistry; Biology; Cancer research; Genetics; DNA; Gene; Polymerase","retraction":null,"screen_n_in":null,"score":{"opus":0.02386045222621364,"gpt":0.3273131591371021,"spread":0.3034527069108885,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002251623,0.0003704343,0.000721881,0.0006025662,0.0001015133,0.00001793136,0.0002215962,0.0001619915,0.00126823],"category_scores_gemma":[0.002741704,0.0003222958,0.0001106637,0.001124268,0.0005681052,0.0001141961,0.00006916266,0.0004125874,0.000151925],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004512797,"about_ca_system_score_gemma":0.0004073115,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002604567,"about_ca_topic_score_gemma":0.00007125743,"domain_scores_codex":[0.9964339,0.0005908522,0.000813163,0.0006593206,0.0009249345,0.0005778025],"domain_scores_gemma":[0.9977669,0.0003630413,0.0002389077,0.0009179636,0.0003530651,0.0003601848],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.006706002,0.0002965723,0.004022782,0.0001196946,0.0001094712,0.002132752,0.002580879,0.00001188912,0.9640422,0.0008287139,0.0164746,0.002674412],"study_design_scores_gemma":[0.04771562,0.008284053,0.0985722,0.00390817,0.000348875,0.002645701,0.001593721,0.0008964303,0.7491599,0.007651176,0.07802071,0.001203387],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9607602,0.001934219,0.005492844,0.02440556,0.0007421053,0.00107328,0.00002412179,0.0001770474,0.005390581],"genre_scores_gemma":[0.9828116,0.0000431834,0.003215182,0.01173124,0.001257402,0.0001207052,0.0001270151,0.00008718445,0.0006064496],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2148823,"threshold_uncertainty_score":0.9999229,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2608211931","doi":"10.1158/2159-8290.cd-17-0146","title":"Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of <i>BRCA2</i> Reversion Mutations Associated with Resistance to PARP Inhibitors","year":2017,"lang":"en","type":"article","venue":"Cancer Discovery","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":268,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; Cancer Research UK","keywords":"Reversion; DNA; Mutation; Poly ADP ribose polymerase; DNA damage; Biology; Chemistry; Cancer research; Genetics; Gene; Phenotype","retraction":null,"screen_n_in":null,"score":{"opus":0.02755752012958285,"gpt":0.3162239602348135,"spread":0.2886664401052306,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002485464,0.0001713325,0.0005752082,0.0002321127,0.000230328,0.00004950887,0.0002493658,0.00007753434,0.00004534827],"category_scores_gemma":[0.0002807908,0.0001567308,0.0002513461,0.0005386661,0.0002733908,0.0003900464,0.0000841844,0.000113076,0.000001005675],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003208707,"about_ca_system_score_gemma":0.0002316113,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004392278,"about_ca_topic_score_gemma":0.002609615,"domain_scores_codex":[0.998303,0.00005628474,0.0004837977,0.0003669179,0.000571645,0.0002183551],"domain_scores_gemma":[0.9976384,0.0001274043,0.0008169358,0.0009498405,0.0003614076,0.0001060183],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0007056085,0.0002303945,0.6701787,0.0002517239,0.001906912,0.00001799414,0.0009615931,0.003982125,0.3199809,0.00002710793,0.001608079,0.0001488028],"study_design_scores_gemma":[0.002123624,0.00007463023,0.5263759,0.0009930313,0.001408378,5.661006e-7,0.0002174504,0.0001610931,0.4683644,0.00004791787,0.00005931078,0.0001736372],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9966148,0.0003975249,0.0006034038,0.0004982576,0.0001968379,0.0003202159,0.0007331306,0.00002052893,0.0006153294],"genre_scores_gemma":[0.9986113,0.00005689038,0.0002806824,0.0001542546,0.0000724999,0.00005871102,0.00008637359,0.00002366764,0.0006556358],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1483835,"threshold_uncertainty_score":0.6391298,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2151209400","doi":"10.1073/pnas.1108799108","title":"Iduna is a poly(ADP-ribose) (PAR)-dependent E3 ubiquitin ligase that regulates DNA damage","year":2011,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":262,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Centre hospitalier universitaire de Québec","funders":"National Institute of Neurological Disorders and Stroke; Canadian Institutes of Health Research; National Institutes of Health; National Institute on Drug Abuse; McKnight Foundation","keywords":"Ubiquitin ligase; DNA ligase; Molecular biology; DDB1; DNA repair; Ubiquitin; Biology; Ku70; DNA damage; Cell biology; Biochemistry; Chemistry; DNA","retraction":null,"screen_n_in":null,"score":{"opus":0.1049182062704579,"gpt":0.3338820552357509,"spread":0.228963848965293,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001473055,0.000162805,0.0002719576,0.0002661581,0.0002139584,0.00002259182,0.000714445,0.0001319419,0.0003405846],"category_scores_gemma":[0.00023963,0.0001115919,0.0001442484,0.00067127,0.001295491,0.0005193427,0.0001465964,0.0002438059,0.000009642781],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007968394,"about_ca_system_score_gemma":0.0000894013,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001981129,"about_ca_topic_score_gemma":8.532053e-8,"domain_scores_codex":[0.9970924,0.000008511925,0.000468514,0.0003706754,0.001799971,0.0002599375],"domain_scores_gemma":[0.9987891,0.00007524675,0.0006367212,0.00002398517,0.0003754726,0.0000994223],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.000204069,0.000211586,0.01868389,0.0001658574,0.000071808,1.121097e-7,0.002275413,0.000001214131,0.9438953,0.02586753,0.008054833,0.0005683288],"study_design_scores_gemma":[0.0005698267,0.0001140353,0.08477273,0.0002977455,0.00003106369,0.00003542512,0.0003224981,0.00007732842,0.8741651,0.03903701,0.0004725867,0.000104644],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9549218,0.0002985524,0.000001199756,0.01127126,0.00004595068,0.0003324444,0.00004195984,0.00003669202,0.03305015],"genre_scores_gemma":[0.9944245,0.00007034546,0.001802821,0.002466517,0.0002131737,0.00002458863,3.156899e-7,0.00001090171,0.0009868337],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06973025,"threshold_uncertainty_score":0.4773292,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2142194813","doi":"10.1016/j.cell.2011.10.046","title":"Structural Basis and Sequence Rules for Substrate Recognition by Tankyrase Explain the Basis for Cherubism Disease","year":2011,"lang":"en","type":"article","venue":"Cell","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":252,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"St. Michael's Hospital; Canada Research Chairs; Mount Sinai Hospital; Lunenfeld-Tanenbaum Research Institute; Ontario Institute for Cancer Research; University of Toronto","funders":"National Center for Research Resources; Canadian Institutes of Health Research; Terry Fox Foundation; Human Frontier Science Program; National Institutes of Health; European Molecular Biology Organization; U.S. Department of Energy","keywords":"Ankyrin repeat; Cherubism; Biology; Peptide sequence; Genetics; Ankyrin; Computational biology; Polymerase; Biochemistry; DNA; Gene","retraction":null,"screen_n_in":null,"score":{"opus":0.1007135040464307,"gpt":0.2988541061465599,"spread":0.1981406021001292,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001544257,0.0001331609,0.0001369251,0.0000278128,0.000140529,0.00001873062,0.00006395565,0.00005377201,0.0002991445],"category_scores_gemma":[0.00007028789,0.00009738351,0.00007888435,0.00004667245,0.000124686,0.0001000311,0.000007836945,0.00007001166,0.000009129409],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004997334,"about_ca_system_score_gemma":0.00005777685,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002354402,"about_ca_topic_score_gemma":0.000004602525,"domain_scores_codex":[0.999265,0.00002846182,0.000167867,0.0002433733,0.00009263186,0.0002026578],"domain_scores_gemma":[0.9992749,0.0001908796,0.00008391684,0.0001946679,0.0000980486,0.0001575613],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.01953088,0.0006560787,0.009643706,0.003438618,0.0004191852,0.00007082306,0.01170047,0.000004033788,0.7017956,0.0009415534,0.1253283,0.1264708],"study_design_scores_gemma":[0.00771838,0.000449677,0.008107282,0.0002112171,0.0003672507,0.00001811999,0.000904448,0.0009281213,0.9506245,0.02092039,0.009312446,0.0004381732],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.99362,0.000953227,0.0009240782,0.001124003,0.0001497783,0.001074021,0.001560066,0.00004432796,0.0005504511],"genre_scores_gemma":[0.9937083,0.0002204889,0.002998412,0.001456416,0.0001679212,0.0006201244,0.0003173185,0.00003044665,0.0004806117],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2488289,"threshold_uncertainty_score":0.3971184,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2270704840","doi":"10.1038/nm.4032","title":"Blocking c-Met–mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors","year":2016,"lang":"en","type":"article","venue":"Nature Medicine","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":245,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University","funders":"National Cancer Institute","keywords":"PARP1; Olaparib; Poly ADP ribose polymerase; Cancer research; PARP inhibitor; Synthetic lethality; DNA damage; Cancer cell; Cancer; DNA repair; Biology; Medicine; Polymerase; Enzyme; Internal medicine; DNA; Biochemistry","retraction":null,"screen_n_in":null,"score":{"opus":0.005994849007095061,"gpt":0.2822921896554457,"spread":0.2762973406483506,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005140593,0.0003090549,0.0007791877,0.0003307354,0.0000649729,0.000003797731,0.0001845347,0.000356355,0.0004350242],"category_scores_gemma":[0.002318259,0.0001800006,0.0001189627,0.0006923355,0.0004049441,0.0001239212,0.00003857567,0.0005340718,0.00003587153],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001600349,"about_ca_system_score_gemma":0.0001320229,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002148553,"about_ca_topic_score_gemma":0.000003573435,"domain_scores_codex":[0.9975109,0.00009610106,0.0006454558,0.0004547822,0.000917522,0.0003752487],"domain_scores_gemma":[0.9974174,0.0009699201,0.0004425365,0.0005961086,0.000356042,0.000217958],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0003258187,0.0001108243,0.0159101,0.0003473116,0.0001175479,0.00007505946,0.000311107,4.24379e-7,0.9621921,0.0002679074,0.009729458,0.01061235],"study_design_scores_gemma":[0.007902556,0.001027069,0.02212643,0.005047561,0.0001634539,0.00004827975,0.00006089894,0.000009990393,0.9420499,0.000413004,0.02094397,0.0002069323],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9738521,0.01435122,0.0005800572,0.006507809,0.002421415,0.0007785641,0.00001270665,0.0001843704,0.00131174],"genre_scores_gemma":[0.9947329,0.0009315015,0.0003774808,0.001926169,0.001611598,0.00005388452,0.00003401158,0.00004754858,0.0002849346],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02088076,"threshold_uncertainty_score":0.7340213,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2124470568","doi":"10.1158/0008-5472.can-10-2352","title":"Contextual Synthetic Lethality of Cancer Cell Kill Based on the Tumor Microenvironment","year":2010,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":244,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Cancer Research UK; Abbott Laboratories","keywords":"PARP inhibitor; PARP1; Poly ADP ribose polymerase; Clonogenic assay; Cancer research; RAD51; Synthetic lethality; Biology; Cancer cell; DNA damage; DNA repair; In vivo; Molecular biology; Cancer; Polymerase; DNA; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.07678439385390248,"gpt":0.4114094948835611,"spread":0.3346251010296586,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001338129,0.0001540725,0.0002680148,0.00008309939,0.0001551792,0.0000159048,0.0002960301,0.00008004921,0.01411661],"category_scores_gemma":[0.0001181469,0.0001037425,0.0001129162,0.0002151459,0.0009423313,0.00003188911,0.00005354662,0.000994044,0.00008008177],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005307477,"about_ca_system_score_gemma":0.000632363,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003404403,"about_ca_topic_score_gemma":0.0007057317,"domain_scores_codex":[0.9975846,0.0002616364,0.0002792946,0.0003835461,0.001018831,0.0004721106],"domain_scores_gemma":[0.9980396,0.000598042,0.000093121,0.0008609109,0.0002259957,0.000182316],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0006867168,0.0003332554,0.004637814,0.0001436632,0.0000339065,0.00001338723,0.0002489471,0.00004906213,0.9820783,0.0003363907,0.00910469,0.002333933],"study_design_scores_gemma":[0.001767196,0.0003006747,0.008197361,0.0002929453,0.00002207486,0.000003046475,0.0002286183,0.0001895387,0.9139318,0.00008648985,0.07486118,0.0001190496],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9771431,0.00123677,0.00001858663,0.01329071,0.0003352785,0.0009404046,0.0001754318,0.00002050349,0.006839198],"genre_scores_gemma":[0.9947621,0.0003940443,0.00005199972,0.002231168,0.0003083699,0.0008274161,0.000004562031,0.00003869401,0.001381663],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06814641,"threshold_uncertainty_score":0.9867846,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2593067736","doi":"10.1158/1078-0432.ccr-16-2796","title":"A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline <i>BRCA1/2</i> -Mutated Ovarian Carcinoma or Other Solid Tumors","year":2017,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":236,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"PARP inhibitor; Ovarian cancer; Germline; Medicine; Cancer research; Germline mutation; Ovarian carcinoma; Internal medicine; Oncology; Cancer; Mutation; Poly ADP ribose polymerase; Biology; Genetics; DNA; Polymerase","retraction":null,"screen_n_in":null,"score":{"opus":0.2419675665224092,"gpt":0.5440788431986607,"spread":0.3021112766762516,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002826676,0.000264121,0.0009271092,0.0001919633,0.00056674,0.0000619327,0.0007928666,0.0001839239,0.0007598149],"category_scores_gemma":[0.001083489,0.0001515566,0.0001405919,0.0006159633,0.001349377,0.0001637186,0.0004274556,0.001501098,0.00001377856],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003265453,"about_ca_system_score_gemma":0.001539914,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003571556,"about_ca_topic_score_gemma":0.004057568,"domain_scores_codex":[0.9948798,0.0008385659,0.001250955,0.0007391693,0.001575267,0.0007162833],"domain_scores_gemma":[0.9959685,0.000371266,0.0005155681,0.001857298,0.0009528073,0.0003346178],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.03324781,0.01495332,0.9400382,0.00007435359,0.0001693859,0.00008691428,0.001086474,0.000008601511,0.000302668,0.00001130622,0.003196799,0.006824173],"study_design_scores_gemma":[0.1008298,0.02538124,0.8667176,0.0007753988,0.00007338111,0.000003396245,0.0003978524,0.0001177936,0.002906216,0.0000631034,0.002485559,0.0002486918],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9937222,0.00006553961,0.000002389287,0.002244046,0.0004094722,0.002967982,0.0001180947,0.00002445435,0.0004458282],"genre_scores_gemma":[0.9973487,0.00002209593,0.00004331351,0.0005309042,0.0005140903,0.0004556414,0.000009544421,0.00007346911,0.001002197],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0733206,"threshold_uncertainty_score":0.831944,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null}]}